

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Novel strategies for the treatment of myelofibrosis... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1662/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1662" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology" />
    
            <meta name="og:title" content="F1000Research Article: Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology.">
            <meta name="og:description" content="Read the latest article version by Zimran Eran, Maria Zingariello, Maria Teresa Bochicchio, Claudio Bardelli, Anna Rita Migliaccio, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="20338">
            <meta name="article-id" content="18581">
            <meta name="dc.title" content="Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology">
            <meta name="dc.description" content="Myelofibrosis is the advanced stage of the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), characterized by systemic inflammation, hematopoietic failure in the bone marrow, and development of extramedullary hematopoiesis, mainly in the spleen. The only potentially curative therapy for this disease is hematopoietic stem cell transplantation, an option that may be offered only to those patients with a compatible donor and with an age and functional status that may face its toxicity. By contrast, with the Philadelphia-positive MPNs that can be dramatically modified by inhibitors of the novel BCR-ABL fusion-protein generated by its genetic lesion, the identification of the molecular lesions that lead to the development of myelofibrosis has not yet translated into a treatment that can modify the natural history of the disease. Therefore, the cure of myelofibrosis remains an unmet clinical need. However, the excitement raised by the discovery of the genetic lesions has inspired additional studies aimed at elucidating the mechanisms driving these neoplasms towards their final stage. These studies have generated the feeling that the cure of myelofibrosis will require targeting both the malignant stem cell clone and its supportive microenvironment. We will summarize here some of the biochemical alterations recently identified in MPNs and the novel therapeutic approaches currently under investigation inspired by these discoveries.">
            <meta name="dc.subject" content="Myelofibrosis, p53, transforming growth factor beta, combination therapy, MDM2 inhibitors, transforming growth factor beta inhibitors, animal models,  pre-clinical studies">
            <meta name="dc.creator" content="Eran, Zimran">
            <meta name="dc.creator" content="Zingariello, Maria">
            <meta name="dc.creator" content="Bochicchio, Maria Teresa">
            <meta name="dc.creator" content="Bardelli, Claudio">
            <meta name="dc.creator" content="Migliaccio, Anna Rita">
            <meta name="dc.date" content="2019/09/19">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.18581.1">
            <meta name="dc.source" content="F1000Research 2019 8:1662">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Myelofibrosis">
            <meta name="prism.keyword" content="p53">
            <meta name="prism.keyword" content="transforming growth factor beta">
            <meta name="prism.keyword" content="combination therapy">
            <meta name="prism.keyword" content="MDM2 inhibitors">
            <meta name="prism.keyword" content="transforming growth factor beta inhibitors">
            <meta name="prism.keyword" content="animal models">
            <meta name="prism.keyword" content="pre-clinical studies">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/09/19">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1662">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.18581.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1662">
            <meta name="citation_title" content="Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology">
            <meta name="citation_abstract" content="Myelofibrosis is the advanced stage of the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), characterized by systemic inflammation, hematopoietic failure in the bone marrow, and development of extramedullary hematopoiesis, mainly in the spleen. The only potentially curative therapy for this disease is hematopoietic stem cell transplantation, an option that may be offered only to those patients with a compatible donor and with an age and functional status that may face its toxicity. By contrast, with the Philadelphia-positive MPNs that can be dramatically modified by inhibitors of the novel BCR-ABL fusion-protein generated by its genetic lesion, the identification of the molecular lesions that lead to the development of myelofibrosis has not yet translated into a treatment that can modify the natural history of the disease. Therefore, the cure of myelofibrosis remains an unmet clinical need. However, the excitement raised by the discovery of the genetic lesions has inspired additional studies aimed at elucidating the mechanisms driving these neoplasms towards their final stage. These studies have generated the feeling that the cure of myelofibrosis will require targeting both the malignant stem cell clone and its supportive microenvironment. We will summarize here some of the biochemical alterations recently identified in MPNs and the novel therapeutic approaches currently under investigation inspired by these discoveries.">
            <meta name="citation_description" content="Myelofibrosis is the advanced stage of the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), characterized by systemic inflammation, hematopoietic failure in the bone marrow, and development of extramedullary hematopoiesis, mainly in the spleen. The only potentially curative therapy for this disease is hematopoietic stem cell transplantation, an option that may be offered only to those patients with a compatible donor and with an age and functional status that may face its toxicity. By contrast, with the Philadelphia-positive MPNs that can be dramatically modified by inhibitors of the novel BCR-ABL fusion-protein generated by its genetic lesion, the identification of the molecular lesions that lead to the development of myelofibrosis has not yet translated into a treatment that can modify the natural history of the disease. Therefore, the cure of myelofibrosis remains an unmet clinical need. However, the excitement raised by the discovery of the genetic lesions has inspired additional studies aimed at elucidating the mechanisms driving these neoplasms towards their final stage. These studies have generated the feeling that the cure of myelofibrosis will require targeting both the malignant stem cell clone and its supportive microenvironment. We will summarize here some of the biochemical alterations recently identified in MPNs and the novel therapeutic approaches currently under investigation inspired by these discoveries.">
            <meta name="citation_keywords" content="Myelofibrosis, p53, transforming growth factor beta, combination therapy, MDM2 inhibitors, transforming growth factor beta inhibitors, animal models,  pre-clinical studies">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Zimran Eran">
            <meta name="citation_author_institution" content="Department of Hematology, Hadassah University Center, Jerusalem, Israel">
            <meta name="citation_author" content="Maria Zingariello">
            <meta name="citation_author_institution" content="Unit of Microscopic and Ultrastructural Anatomy, Department of Medicine, University Campus Bio-Medico, Rome, Italy">
            <meta name="citation_author" content="Maria Teresa Bochicchio">
            <meta name="citation_author_institution" content="Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), IRCCS, Meldola (FC), Italy">
            <meta name="citation_author" content="Claudio Bardelli">
            <meta name="citation_author_institution" content="Dipartimento di Scienze Biomediche e NeuroMotorie, Alma Mater Studiorum - Universit&agrave; di Bologna, Bologna, Italy">
            <meta name="citation_author" content="Anna Rita Migliaccio">
            <meta name="citation_author_institution" content="Dipartimento di Scienze Biomediche e NeuroMotorie, Alma Mater Studiorum - Universit&agrave; di Bologna, Bologna, Italy">
            <meta name="citation_publication_date" content="2019/09/19">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1662">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.18581.1">
            <meta name="citation_firstpage" content="1662">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1662/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1662.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=20338 /> <input type=hidden id=articleId name=articleId value=18581 /> <input type=hidden id=xmlUrl value="/articles/8-1662/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1662-v1.xml"> <input type=hidden id=article_uuid value=afbd6ce0-7cf7-4ded-8297-d9f865d0299a /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.18581.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.18581.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1662"
  },
  "headline": "Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the...",
  "datePublished": "2019-09-19T16:29:24",
  "dateModified": "2019-09-19T16:29:24",
  "author": [
    {
      "@type": "Person",
      "name": "Zimran Eran"
    },    {
      "@type": "Person",
      "name": "Maria Zingariello"
    },    {
      "@type": "Person",
      "name": "Maria Teresa Bochicchio"
    },    {
      "@type": "Person",
      "name": "Claudio Bardelli"
    },    {
      "@type": "Person",
      "name": "Anna Rita Migliaccio"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Myelofibrosis is the advanced stage of the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), characterized by systemic inflammation, hematopoietic failure in the bone marrow, and development of extramedullary hematopoiesis, mainly in the spleen. The only potentially curative therapy for this disease is hematopoietic stem cell transplantation, an option that may be offered only to those patients with a compatible donor and with an age and functional status that may face its toxicity. By contrast, with the Philadelphia-positive MPNs that can be dramatically modified by inhibitors of the novel BCR-ABL fusion-protein generated by its genetic lesion, the identification of the molecular lesions that lead to the development of myelofibrosis has not yet translated into a treatment that can modify the natural history of the disease. Therefore, the cure of myelofibrosis remains an unmet clinical need. However, the excitement raised by the discovery of the genetic lesions has inspired additional studies aimed at elucidating the mechanisms driving these neoplasms towards their final stage. These studies have generated the feeling that the cure of myelofibrosis will require targeting both the malignant stem cell clone and its supportive microenvironment. We will summarize here some of the biochemical alterations recently identified in MPNs and the novel therapeutic approaches currently under investigation inspired by these discoveries."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1662.html",
            "name": "Novel strategies for the treatment of myelofibrosis driven by recent..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Novel strategies for the treatment of myelofibrosis driven by recent... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=20338 data-id=18581 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18581.1" data-recommended="" data-doi="10.12688/f1000research.18581.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1662/v1/pdf?article_uuid=afbd6ce0-7cf7-4ded-8297-d9f865d0299a" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-18581-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-18581-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-18581-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Eran Z, Zingariello M, Bochicchio MT <em>et al.</em> Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1662 (<a class=new-orange href="https://doi.org/10.12688/f1000research.18581.1" target=_blank>https://doi.org/10.12688/f1000research.18581.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-18581-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=18581 id=track-article-signin-18581 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18581?target=/articles/8-1662.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20338 /> <input name=articleId type=hidden value=18581 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Zimran Eran<sup>1</sup>,&nbsp;</span><span class="">Maria Zingariello<sup>2</sup>,&nbsp;</span><span class="">Maria Teresa Bochicchio<a href="https://orcid.org/0000-0001-9299-9189" target=_blank id=author-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-9299-9189</div><sup>3</sup>,&nbsp;</span><span class="">Claudio Bardelli<sup>4</sup>,&nbsp;</span><span class=""><a href="mailto:annarita.migliaccio@unibo.it" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Anna Rita Migliaccio</span></a><a href="https://orcid.org/0000-0003-1800-271X" target=_blank id=author-orcid-4><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-4><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1800-271X</div><sup>4</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Zimran Eran<sup>1</sup>,&nbsp;</span><span class="">Maria Zingariello<sup>2</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Maria Teresa Bochicchio<a href="http://orcid.org/0000-0001-9299-9189" target=_blank id=mauthor-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-9299-9189</div><sup>3</sup>,&nbsp;</span><span class="">Claudio Bardelli<sup>4</sup>,&nbsp;</span><span class=""><a href="mailto:annarita.migliaccio@unibo.it" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Anna Rita Migliaccio</span></a><a href="http://orcid.org/0000-0003-1800-271X" target=_blank id=mauthor-orcid-4><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-4><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1800-271X</div><sup>4</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 19 Sep 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.18581.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Hematology, Hadassah University Center, Jerusalem, Israel<br/> <sup>2</sup> Unit of Microscopic and Ultrastructural Anatomy, Department of Medicine, University Campus Bio-Medico, Rome, Italy<br/> <sup>3</sup> Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), IRCCS, Meldola (FC), Italy<br/> <sup>4</sup> Dipartimento di Scienze Biomediche e NeuroMotorie, Alma Mater Studiorum - Universit&agrave; di Bologna, Bologna, Italy<br/> <p> <div class=margin-bottom> Zimran Eran <br/> <span>Roles: </span> Conceptualization, Writing  Review & Editing </div> <div class=margin-bottom> Maria Zingariello <br/> <span>Roles: </span> Conceptualization, Writing  Review & Editing </div> <div class=margin-bottom> Maria Teresa Bochicchio <br/> <span>Roles: </span> Writing  Review & Editing </div> <div class=margin-bottom> Claudio Bardelli <br/> <span>Roles: </span> Project Administration </div> <div class=margin-bottom> Anna Rita Migliaccio <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=56999-53831></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=49617-47367></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Myelofibrosis is the advanced stage of the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), characterized by systemic inflammation, hematopoietic failure in the bone marrow, and development of extramedullary hematopoiesis, mainly in the spleen. The only potentially curative therapy for this disease is hematopoietic stem cell transplantation, an option that may be offered only to those patients with a compatible donor and with an age and functional status that may face its toxicity. By contrast, with the Philadelphia-positive MPNs that can be dramatically modified by inhibitors of the novel BCR-ABL fusion-protein generated by its genetic lesion, the identification of the molecular lesions that lead to the development of myelofibrosis has not yet translated into a treatment that can modify the natural history of the disease. Therefore, the cure of myelofibrosis remains an unmet clinical need. However, the excitement raised by the discovery of the genetic lesions has inspired additional studies aimed at elucidating the mechanisms driving these neoplasms towards their final stage. These studies have generated the feeling that the cure of myelofibrosis will require targeting both the malignant stem cell clone and its supportive microenvironment. We will summarize here some of the biochemical alterations recently identified in MPNs and the novel therapeutic approaches currently under investigation inspired by these discoveries. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Myelofibrosis, p53, transforming growth factor beta, combination therapy, MDM2 inhibitors, transforming growth factor beta inhibitors, animal models, pre-clinical studies </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Anna Rita Migliaccio (<a href="mailto:annarita.migliaccio@unibo.it">annarita.migliaccio@unibo.it</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Anna Rita Migliaccio </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This study was supported by grants from the National Cancer Institute (P01-CA108671), National Heart, Lung, and Blood Institute (1R01-HL116329) and Associazione Italiana Ricerca Cancro (AIRC 17608). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2019 Eran Z <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Eran Z, Zingariello M, Bochicchio MT <em>et al.</em> Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1662 (<a href="https://doi.org/10.12688/f1000research.18581.1" target=_blank>https://doi.org/10.12688/f1000research.18581.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 19 Sep 2019, <b>8</b>(F1000 Faculty Rev):1662 (<a href="https://doi.org/10.12688/f1000research.18581.1" target=_blank>https://doi.org/10.12688/f1000research.18581.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 19 Sep 2019, <b>8</b>(F1000 Faculty Rev):1662 (<a href="https://doi.org/10.12688/f1000research.18581.1" target=_blank>https://doi.org/10.12688/f1000research.18581.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><p class="" id=d23757e211></p><a name=d23757e213 class=n-a></a><div class="boxed-text panel clearfix"><div class=caption><h3>Editorial note:</h3></div><p class="" id=d23757e218><b>17th October 2019:</b> We have removed the peer review report from Drs Giovanni Martinelli and Maria Teresa Bochicchio. Whilst we are very grateful for their help with the peer review process, later in the revision process Dr Maria Teresa Bochicchio was added as an author of this article. As authorship or sharing an affiliation with an author precludes someone from participating in the peer review process, we have discounted their review for this article. As sufficient other reviewers have positively reviewed this article and the authorship change came after the peer review process, this article is still considered to have passed peer review.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d23757e227>Introduction</h2><p class="" id=d23757e230>Overt myelofibrosis (MF) is the final stage of several disease entities collectively referred to as the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) that include polycythemia vera (PV), essential thrombocythemia (ET), and prefibrotic or early stage primary myelofibrosis (pre-MF) and can also arise <i>de novo</i> as overt fibrotic-stage primary myelofibrosis (PMF)<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup> These diseases share common clinical features including constitutional and microvascular symptoms, splenomegaly, a high risk of thromboembolic and hemorrhagic complications, and a propensity to progress to a form of acute myeloid leukemia (AML) termed MPN-blast phase (MPN-BP). Early studies have identified that MPNs arise within the hematopoietic stem/progenitor cell (HSPC) compartment, and recent advances have largely elucidated its molecular pathophysiology<sup><a href="#ref-3">3</a><a href="#ref-5">5</a></sup>. Constitutive activation of the JAKSTAT signaling pathway driven by one of several canonical somatic mutations results in myeloproliferation and contributes to genomic instability. Acquisition of additional genetic aberrations eventually leads to disease progression<sup><a href="#ref-5">5</a></sup>. While PV, ET, and pre-MF are usually indolent hematological malignancies with a median survival spanning decades or several years, overt MF, which include PMF, carries worse prognosis and severely affects the patients quality of life. Usually, MPN-BP has a prognosis of only several months<sup><a href="#ref-6">6</a></sup>. The disease progression of MF exhibits a great range of patient-to-patient variability. The detailed genetic information currently available on large numbers of patients is providing evidence-based criteria for their risk stratification, which, in the future, may provide the basis for personalized therapy.</p><p class="" id=d23757e258>In contrast to the significant progress made in understanding the diseases pathogenesis, treatment for MF remains largely palliative. Although we can effectively reduce symptoms and prevent thromboembolic complications, a treatment that can modify the course of the disease and prevent progression to MPN-BP is lacking. The only therapeutic option that offers potential cure is allogeneic hematopoietic stem cell (HSC) transplantation (HSCT), but this approach is limited by the lack of donors to all patients and by associated morbidity and mortality. Improving the survival of patients with MF is a major unmet need in malignant hematology. Better understanding of the pathological pathways involved in MF disease progression has ushered the development of novel treatment strategies aimed at slowing or even reversing disease progression and prolonging patient survival. An excellent review on the genetic basis of MPNs has been recently published by Vainchenker <i>et al</i>. in <i>F1000Research</i><sup><a href="#ref-5">5</a></sup>. Here, we will summarize scientific information that is driving the search for a cure in MPNs, focusing our discussion on the most recent strategies targeting the microenvironment that are currently under investigation.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d23757e273>Mutational landscape in MPNs</h2><p class="" id=d23757e276>In 2005, four groups reported the identification of a point mutation in exon 14 of the <i>JAK2</i> gene, <i>JAK2</i>V617F, in over 95% of patients with PV and 5060% of patients with ET and PMF<sup><a href="#ref-7">7</a><a href="#ref-10">10</a></sup>. JAK2 is the tyrosine kinase that represents the first signal transduction element of the receptors for erythropoietin (EPO), thrombopoietin (TPO), and granulocyte-colony stimulating factor (GSCF)<sup><a href="#ref-5">5</a></sup>. As such, JAK2 is necessary for normal hematopoietic cell growth and differentiation. <i>JAK2</i>V617 affects the inhibitory domain of the protein, rendering it constitutively active, independent of extracellular activation by the physiologic ligands. <i>JAK2</i> exon 12 mutations have later been found to drive most cases of <i>JAK2</i>V617-negative PV<sup><a href="#ref-11">11</a></sup>. Inactivating mutations in the gene encoding the TPO receptor (<i>MPL</i>) have been identified in 35% of ET and PMF cases<sup><a href="#ref-12">12</a></sup>. In 2013, frameshift mutations in exon 9 of the calreticulin (<i>CALR</i>) gene, encoding for an endoplasmic reticulum chaperone protein that interacts with MPL, were found in the majority of <i>JAK2</i>V617F and <i>MPL</i> mutation-negative ET and PMF patients, thereby completing the missing piece in the puzzle of MPN driver mutations<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. In up to 10% of patients with ET and 15% of patients with PMF, a driver mutation cannot be identified. These triple-negative MPNs may be driven by non-canonical mutations in <i>JAK2</i> or <i>MPL</i> or by genetic lesions in other mediators of the JAKSTAT pathway such as <i>LNK</i> or <i>PPM1D</i><sup><a href="#ref-5">5</a>,<a href="#ref-15">15</a></sup>.</p><p class="" id=d23757e353>Advances in genotyping, such as the application of next-generation sequencing and high-resolution chromosomal microarrays, have led to the discovery of additional somatic mutations that usually arise following acquisition of the driver mutations but can also precede them and that can contribute to disease progression and transformation to MPN-BP. These mutations affect genes involved in epigenetic regulation and splicing, such as <i>ASXL1</i>, <i>DNMT3A</i>, <i>TET2</i>, <i>SRSF2, U2AF1</i>, and <i>SF3B1</i>, as well as signaling and apoptosis, and were found across all myeloid malignancies<sup><a href="#ref-5">5</a></sup>. Mutations in <i>ASXL1</i>, <i>SRSF2</i>, <i>EZH2</i>, and <i>IDH1/2</i> have been associated with shortened survival and higher risk of progression to MPN-BP<sup><a href="#ref-16">16</a></sup>. Mutations in <i>U2AF1</i> have been associated with anemia and additional poor prognostic features<sup><a href="#ref-17">17</a></sup>. Mutations or other genetic lesions affecting the tumor suppressor p53 have been shown to play a central role in progression to MPN-BP and are highly predictive of leukemic transformation and poor outcomes<sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a></sup>. The growing importance of genomic analysis in MPN patient assessment is reflected by the advent of updated risk stratification models integrating molecular and cytogenetic profiles with the more traditional clinical and morphological parameters to guide management decisions such as referral to HSCT<sup><a href="#ref-20">20</a><a href="#ref-22">22</a></sup>. For example, a Genetics-based International Prognostic Scoring System (GIPSS) has been proposed that is based exclusively on mutational and cytogenetic markers<sup><a href="#ref-20">20</a></sup>. Recently, comprehensive genomic characterization of 2,035 MPN patients identified distinct genetic subgroups that correlate well with clinical course and prognosis and may arguably provide more accurate classification than current disease entities<sup><a href="#ref-15">15</a></sup>. We hope that this influx of advanced molecular diagnostics will ultimately contribute to more personalized tailoring of treatment strategies and translate to improved survival.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d23757e425>Optimization of current treatment approaches for MF</h2><p class="" id=d23757e428>Great efforts are dedicated to improving the treatment armamentarium currently available for MF. We will focus on what we perceive are the main trajectories within these efforts: development of second-generation JAK inhibitors, advances in transplantation medicine and its utilization for MF, and evaluation of novel agents. Although a complete summary of current treatment approaches is beyond the scope of this review, it is important to note the emerging role for pegylated interferon formulations in the treatment of early stage (proliferative) MF<sup><a href="#ref-23">23</a><a href="#ref-25">25</a></sup> and of hypomethylating agents in accelerated and MPN-BP<sup><a href="#ref-26">26</a><a href="#ref-28">28</a></sup>.</p><div class=section><a name=d23757e445 class=n-a></a><h3 class=section-title>JAK inhibitors</h3><p class="" id=d23757e450>Following the discovery of <i>JAK2</i>V617, a non-selective JAK1/2 inhibitor, ruxolitinib, was developed and has been shown in two pivotal phase III studies to induce significant spleen volume reduction and improvement in constitutional symptoms, leading to its approval by the USA and European regulatory agencies for intermediate-2 and high-risk MF<sup><a href="#ref-29">29</a>,<a href="#ref-30">30</a></sup>. The widespread use of ruxolitinib has changed the therapeutic landscape and significantly impacted the quality of life of many MF patients. Moreover, long-term follow up of the COMFORT studies has suggested a survival advantage with the use of ruxolitinib<sup><a href="#ref-31">31</a></sup>. Since the biological effects of this drug on mutation allele burden or bone marrow histological findings have been inconsistent and overall modest<sup><a href="#ref-32">32</a><a href="#ref-34">34</a></sup>, other analyses have attributed the beneficial effect of ruxolitinib on survival to the attenuation of systemic inflammation and reversal of cachexia owing to spleen volume reduction. Furthermore, the use of ruxolitinib is limited in patients with anemia and thrombocytopenia. These considerations inspired the development of second-generation JAK inhibitors that lack myelosuppressive effects and may allow effective treatment for patients with cytopenias. Three second-generation JAK inhibitors have been evaluated in phase III clinical trials, and their efficacy results are summarized in <a href="#T1">Table 1</a>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Summary of the efficacy outcomes of the six larger scale (phase II and III) second-generation JAK inhibitor studies.</h3><p id=d23757e487>BAT, best available therapy; DIPSS, Dynamic International Prognostic Scoring System; FED, fedratinib; IPSS, International Prognostic Scoring System; JAK, Janus kinase; MF, myelofibrosis; MOM, momelotinib; PAC, pacritinib; PLT, platelet; pts, patients; RBC, red blood cell; RUX, ruxolitinib; SVR, spleen volume reduction; TSS, total symptom score.</p></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d23757e491 class=n-a></a><thead><a name=d23757e493 class=n-a></a><tr><a name=d23757e495 class=n-a></a><th align=center colspan=1 rowspan=1 valign=top><a name=d23757e497 class=n-a></a>Drug</th><th align=center colspan=1 rowspan=1 valign=top><a name=d23757e500 class=n-a></a>Trial</th><th align=center colspan=1 rowspan=1 valign=top><a name=d23757e503 class=n-a></a>Patient population</th><th align=center colspan=1 rowspan=1 valign=top><a name=d23757e506 class=n-a></a>Number<br class=br>of<br class=br>patients</th><th align=center colspan=1 rowspan=1 valign=top><a name=d23757e513 class=n-a></a>Comparator</th><th align=center colspan=1 rowspan=1 valign=top><a name=d23757e517 class=n-a></a>Spleen<br class=br>response<br class=br>(SVR35%) at<br class=br>24 weeks</th><th align=center colspan=1 rowspan=1 valign=top><a name=d23757e526 class=n-a></a>Symptom<br class=br>response<br class=br>(50%<br class=br>reduction in<br class=br>TSS) at 24<br class=br>weeks</th><th align=center colspan=1 rowspan=1 valign=top><a name=d23757e539 class=n-a></a>Cytopenia</th><th align=center colspan=1 rowspan=1 valign=top><a name=d23757e542 class=n-a></a>Ref.</th></tr></thead><tbody><a name=d23757e546 class=n-a></a><tr><a name=d23757e548 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e550 class=n-a></a>PAC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e553 class=n-a></a>PERSIST-1<br class=br>(phase III)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e558 class=n-a></a>JAK-inhibitor-nave<br class=br>pts with DIPSS<br class=br>intermediate or<br class=br>high-risk MF, with<br class=br>no exclusion for<br class=br>baseline anemia or<br class=br>thrombocytopenia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e574 class=n-a></a>327</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e577 class=n-a></a>BAT (2:1)<br class=br>excluding JAK<br class=br>inhibitors</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e585 class=n-a></a>19% in PAC<br class=br>group versus<br class=br>5% in BAT<br class=br>group<br class=br><i>(P &lt;</i>0.0003)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e598 class=n-a></a>19% in PAC<br class=br>versus 10% in<br class=br>BAT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e605 class=n-a></a>25% who were<br class=br>transfusion<br class=br>dependent achieved<br class=br>transfusion<br class=br>independence.<br class=br>Responses for pts<br class=br>with low PLT counts</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e621 class=n-a></a><a href="#ref-35">35</a></td></tr><tr><a name=d23757e626 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e628 class=n-a></a>PAC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e631 class=n-a></a>PERSIST-2<br class=br>(phase III)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e636 class=n-a></a>MF pts with PLT<br class=br>counts &lt;100 x 10<sup>9</sup>/L</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e644 class=n-a></a>311</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e647 class=n-a></a>BAT (2:1)<br class=br>including RUX<br class=br>(48%)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e655 class=n-a></a>18% in PAC<br class=br>group versus<br class=br>3% in BAT<br class=br>group</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e664 class=n-a></a>25% in PAC<br class=br>group versus<br class=br>14% in BAT<br class=br>group</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e673 class=n-a></a>Reduced transfusion<br class=br>burden in PAC group</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e678 class=n-a></a><a href="#ref-36">36</a></td></tr><tr><a name=d23757e682 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e684 class=n-a></a>MOM</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e687 class=n-a></a>SIMPLIFY-1<br class=br>(phase III)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e692 class=n-a></a>JAK-inhibitor-nave<br class=br>adult pts with IPSS<br class=br>intermediate-2<br class=br>or high-risk MF,<br class=br>or symptomatic<br class=br>intermediate-1 MF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e705 class=n-a></a>432</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e708 class=n-a></a>Ruxolitinib (1:1)<br class=br>(the only head-<br class=br>to-head study)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e716 class=n-a></a>26.5% in<br class=br>MOM group<br class=br>versus 29%<br class=br>in RUX group<br class=br>(non-inferior)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e727 class=n-a></a>28.4% in MOM<br class=br>group versus<br class=br>42.2% in RUX<br class=br>group (inferior)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e736 class=n-a></a>66.5% of MOM<br class=br>pts transfusion<br class=br>independent at 24<br class=br>weeks versus 49.3%<br class=br>with RUX</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e747 class=n-a></a><a href="#ref-37">37</a></td></tr><tr><a name=d23757e751 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e753 class=n-a></a>MOM</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e756 class=n-a></a>SIMPLIFY-2<br class=br>(phase III)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e761 class=n-a></a>Adult MF patients<br class=br>who had suboptimal<br class=br>responses or<br class=br>hematological side<br class=br>effects with RUX </td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e772 class=n-a></a>156</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e775 class=n-a></a>BAT (RUX in<br class=br>89%)<br class=br>(2:1)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e783 class=n-a></a>7% in MOM<br class=br>group versus<br class=br>6% in RUX<br class=br>group<br class=br>(not superior)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e794 class=n-a></a>26% in MOM<br class=br>group versus<br class=br>6% in BAT<br class=br>group<br class=br>(<i>P</i> = 0.0006)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e808 class=n-a></a>RBC transfusion<br class=br>independence at 24<br class=br>weeks achieved by<br class=br>43% of MOM group<br class=br>versus 21% of BAT<br class=br>group</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e821 class=n-a></a><a href="#ref-38">38</a></td></tr><tr><a name=d23757e825 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e827 class=n-a></a>FED<br class=br>(two<br class=br>doses)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e834 class=n-a></a>JAKARTA-1<br class=br>(phase III)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e839 class=n-a></a>JAK-inhibitor-<br class=br>nave pts with<br class=br>intermediate-1 to<br class=br>high-risk MF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e848 class=n-a></a>289</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e851 class=n-a></a>Placebo (2:1)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e855 class=n-a></a>36% and<br class=br>40% in FED<br class=br>400 mg and<br class=br>500 mg groups,<br class=br>respectively,<br class=br>versus 1% with<br class=br>placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e871 class=n-a></a>36% and<br class=br>34% for the<br class=br>two doses<br class=br>versus 7% with<br class=br>placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e882 class=n-a></a>Not reported<br class=br>(drug<br class=br>myelosuppressive)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e889 class=n-a></a><a href="#ref-39">39</a></td></tr><tr><a name=d23757e894 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e896 class=n-a></a>FED<br class=br>(400<br class=br>mg)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e903 class=n-a></a>JAKARTA-2<br class=br>(phase II)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e908 class=n-a></a>RUX resistant or<br class=br>intolerant patients<br class=br>with intermediate or<br class=br>high-risk MF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e917 class=n-a></a>97</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e920 class=n-a></a>None<br class=br>(single-arm<br class=br>study)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e928 class=n-a></a>55% (46 of 83<br class=br>evaluable pts)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e933 class=n-a></a>26% (23 of 90<br class=br>evaluable pts)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e938 class=n-a></a>Not reported (drug<br class=br>myelosuppressive)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d23757e943 class=n-a></a><a href="#ref-40">40</a></td></tr></tbody></table></div><p class="" id=d23757e950>Pacritinib is an oral multi-kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R. The PERSIST-1 study randomized ruxolitinib-nave patients irrespective of platelet count to either pacritinib at a dose of 400 mg once daily or best available therapy (BAT) excluding ruxolitinib. Spleen and symptom responses were significantly superior in the pacritinib arm. Notably, patients with low platelet counts achieved comparable benefits. Toxicities were overall manageable<sup><a href="#ref-35">35</a></sup>. PERSIST-2 recruited only patients with thrombocytopenia and randomized them to pacritinib at one of two doses or BAT including ruxolitinib. Prior use of ruxolitinib was allowed. Pacritinib at both doses was superior to BAT and led to significant spleen and symptom responses, with tolerable myelosuppression<sup><a href="#ref-36">36</a></sup>. The development of pacritinib was halted by a clinical hold placed by the FDA due to suspicion of excess cardiovascular deaths in patients treated with the drug. This hold was subsequently removed, and the results of a new study that may hopefully lead to pacritinibs approval are awaited.</p><p class="" id=d23757e961>Momelotinib is a JAK1/2 inhibitor with activity against activin receptors believed to contribute to a remarkable anemia response, rendering this drug attractive, especially in the setting of transfusion-dependent anemia. The two phase III SIMPLIFY studies that evaluated momelotinib, despite showing a compelling anemia response, each failed to show superiority or non-inferiority in a primary or key-secondary endpoint<sup><a href="#ref-37">37</a>,<a href="#ref-38">38</a></sup>. A more pragmatic study design that would take into account the anemia response and superior tolerability of this drug along with spleen and symptom responses could allow for a better evaluation of this potentially beneficial agent<sup><a href="#ref-41">41</a></sup>. Recently, the development of momelotinib was renewed, and a new phase III study is recruiting patients.</p><p class="" id=d23757e976>Fedratinib is a selective JAK2 inhibitor. The JAKARTA-1 study evaluated two doses of fedratinib versus placebo and showed significantly superior spleen and symptom responses in both treatment arms<sup><a href="#ref-39">39</a></sup>. JAKARTA-2 was a single-arm phase II study evaluating fedratinib in patients who were intolerant of or resistant to ruxolitinib<sup><a href="#ref-40">40</a></sup>. This was the only clinical trial directly evaluating a second-generation JAK inhibitor as second-line treatment, and responses, especially with regards to spleen volume reduction, were compelling for this patient population. The development of fedratinib was also stalled by a clinical hold placed by the FDA due to a suspected association with Wernickes encephalopathy, which was eventually lifted following re-evaluation. The phase III FREEDOM study (NCT03755518) is currently recruiting patients and will hopefully contribute to further development of this drug with apparent potential clinical benefit. Based on the results of the JAKARTA-1 trial, on 16 August 2019, the FDA approved fedratinib for the treatment of adult patients with intermediate-2 or high-risk MF.</p></div><div class=section><a name=d23757e988 class=n-a></a><h3 class=section-title>Bone marrow transplantation</h3><p class="" id=d23757e993>The discovery by Fialkow in 1976 that MPNs are a clonal disorder of HSCs<sup><a href="#ref-3">3</a></sup>, more recently confirmed at the molecular level by the Weissman laboratory<sup><a href="#ref-4">4</a></sup>, led to the hypothesis that MPNs may be cured by HSCT, a procedure which replaces the malignant HSCs of the recipient with healthy ones provided by the donor. However, since the disease also impairs the supportive bone marrow microenvironment, which remains patient derived after transplantation<sup><a href="#ref-42">42</a></sup>, this approach was initially received with skepticism. Reports of long-term survival of transplant recipients coupled by histological evidence of resolution of bone marrow fibrosis eventually provided compelling evidence for the curative potential of this approach<sup><a href="#ref-43">43</a><a href="#ref-46">46</a></sup>. However, HSCT remained limited to a relatively small proportion of patients owing to the older age and frequent comorbidities of most patients and the high non-relapse mortality reported in early studies.</p><p class="" id=d23757e1015>Recently, advances in transplantation medicine and molecular diagnosis are being translated to a consistent improvement in HSCT outcomes in MF<sup><a href="#ref-47">47</a><a href="#ref-49">49</a></sup>. Several factors contribute to the increased utilization and improved outcomes of HSCT for MF treatment: 1) the use of reduced intensity conditioning (RIC) regimens in older patients, which have demonstrated decreased transplant-related mortality with comparable relapse rates and overall survival<sup><a href="#ref-50">50</a><a href="#ref-52">52</a></sup>; 2) increased accessibility to HSCT for patients lacking sibling or matched-unrelated donors owing to advances in the use of alternative donors such as haploidentical donors and cord blood<sup><a href="#ref-53">53</a><a href="#ref-55">55</a></sup>; 3) accumulating data regarding mutational profiles and their prognostic significance allowing earlier and more informed patient selection<sup><a href="#ref-56">56</a></sup>; and 4) accumulating experience with the use of ruxolitinib before or after transplant.</p><p class="" id=d23757e1043>HSCT is presently considered the standard of care in eligible patients with intermediate-2 and high-risk disease<sup><a href="#ref-34">34</a></sup>. There is lack of consensus regarding its use in earlier stages of the disease predicted to have more prolonged survival. A subset of patients classified as having low/intermediate-1 risk disease may eventually experience rapid progression to advanced MF and shortened survival. The recent advances in linking genetic profiles with risk of progression may improve the prediction of disease course and allow us to identify early stage patients who should be considered for HSCT.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d23757e1054>Evaluation of novel agents</h2><p class="" id=d23757e1057>Numerous investigational agents are being evaluated for the treatment of MF alone or in combination with ruxolitinib. These agents were designed with the aim to a) improve anemia, b) deplete the malignant HSCs by targeting molecular alterations downstream of the genetic lesions, c) reduce microenvironmental abnormalities that may synergize with the driver mutations in sustaining proliferation of the malignant HSCs, or d) boost patients immune reactions. Comprehensive reviews focusing on investigational agents for the treatment of MF have been published recently<sup><a href="#ref-57">57</a>,<a href="#ref-58">58</a></sup>. We will highlight several agents representing the above aims that have shown a strong scientific and preclinical rationale and/or encouraging signs of activity in early phase clinical studies.</p><div class=section><a name=d23757e1067 class=n-a></a><h3 class=section-title>Agents that improve anemia</h3><p class="" id=d23757e1072>Activins are members of the transforming growth factor (TGF)- superfamily that inhibit the differentiation of late-stage erythrocyte precursors in a mechanism independent of erythropoietin and are overexpressed in myelodysplastic syndromes (MDS) and in MF. Two agents that antagonize the activity of activins, sotatercept and luspatercept, have demonstrated efficacy in the treatment of anemia in patients with MDS<sup><a href="#ref-59">59</a><a href="#ref-63">63</a></sup>. These agents are currently being evaluated in patients with MF and anemia with promising results in early phase studies<sup><a href="#ref-64">64</a></sup>.</p></div><div class=section><a name=d23757e1087 class=n-a></a><h3 class=section-title>Drugs targeting epigenomic alterations found in malignant HSCs</h3><p class="" id=d23757e1092>Members of the Bromodomain and Extra-Terminal (BET) family of proteins function as readers of histone modification marks, by interacting with acetylated lysine residues on histone tails, and regulate genes that are involved in inflammation and cancer such as <i>MYC, BCL-2</i>, and <i>NF-kB</i><sup><a href="#ref-65">65</a>,<a href="#ref-66">66</a></sup>. The NF-kB pathway downstream to BET has been shown to be activated in MF via JAKSTAT and other inflammatory cytokine signaling<sup><a href="#ref-67">67</a></sup>. In a preclinical study using two MF mouse models, treatment with a BET inhibitor (BETi) resulted in reduction of cytokine production, spleen volume, and bone marrow fibrosis, and these effects were enhanced in combination with ruxolitinib<sup><a href="#ref-68">68</a></sup>. These data indicate that drugs that reduce NFB function and expression of NF-kB target genes might be effective in treating MF<sup><a href="#ref-69">69</a></sup>. CPI-610, a BET inhibitor, is currently being evaluated for the treatment of MF patients, alone or in combination with ruxolitinib (NCT02158858).</p><p class="" id=d23757e1119>While most of the above investigational agents as well as JAK inhibitors target signaling pathways involved in myeloproliferation and systemic inflammation, agents directly targeting MF-HSCs are lacking. The development of such agents has been a major challenge in the effort to improve the therapeutic armamentarium for myeloid malignancies. Imetelstat is an inhibitor of telomerase enzymatic activity<sup><a href="#ref-70">70</a></sup>. The rationale for its use in MF stems from the findings of enhanced telomerase activity in MPN granulocytes<sup><a href="#ref-71">71</a></sup>. A pilot study evaluating the use of single-agent telomerase in 33 patients with intermediate-2 and high-risk MF demonstrated a modest overall response rate (ORR) of 21%; however, in all four patients who achieved a complete response, bone marrow fibrosis was reversed, and a molecular response occurred in three of these patients, suggesting that imetelstat targets the malignant HSCs<sup><a href="#ref-72">72</a></sup>. Preclinical studies confirmed these findings by demonstrating direct targeting of MF-CD34<sup>+</sup> cells by imetelstat, reflected by decreased formation of megakaryocytic colonies and by reduced human chimerism in an immune-deficient mouse xenotransplantation model. Both of these effects were selective to cells from MF patients, but not normal individuals, and sustained over time<sup><a href="#ref-73">73</a></sup>. Recently, a multicenter phase II study evaluating two doses of imetelstat in a cohort of MF patients that progressed after or were refractory to ruxolitinib treatment has demonstrated an estimated twofold prolongation of survival as compared to retrospective reports of comparable patient populations, warranting further clinical testing<sup><a href="#ref-74">74</a></sup>.</p></div><div class=section><a name=d23757e1147 class=n-a></a><h3 class=section-title>Targeting the inflammatory microenvironment</h3><p class="" id=d23757e1152>Several clinical studies have shown that MPN patients express increased levels of inflammatory mediators<sup><a href="#ref-75">75</a></sup>, including the key inflammatory cytokine interleukin-8 (IL-8), the plasma levels of which predict adverse clinical outcomes<sup><a href="#ref-76">76</a></sup>. The pathogenetic role of these cytokines is also supported by the observation that JAK inhibition can attenuate features of MPNs <i>in vivo</i> through the inhibition of cytokine production in mutant and non-mutant cells<sup><a href="#ref-77">77</a></sup>. However, there is limited insight on the pathobiological consequence of aberrant cytokine production in MPNs. It is conceivable that specific targeting of some of the cytokines altered in MPNs may lead to better clinical outcomes than those obtained with JAK inhibitors<sup><a href="#ref-77">77</a></sup>. An altered cytokine pathway that holds potential clinical interest in MF is the lipocalin-2 (LCN2)/interleukin-8 (IL-8) axis and its down-stream signaling via NF-kB. There is evidence that the sequence of events leading to abnormalities in the microenvironment in MF spleens and marrow includes, at least in part, LCN2<sup><a href="#ref-78">78</a></sup>. LCN2 increased the proliferation of splenic endothelial cells, and LCN2 treatment of splenic stromal cells led to increased elaboration of IL-8, which contributes to the creation of an endothelial cell niche supporting the proliferation of MF-HSCs<sup><a href="#ref-79">79</a>,<a href="#ref-80">80</a></sup>. This endothelial cell niche can be disrupted <i>in vitro</i> by reparixin, an antagonist of the receptors for IL-8 CXCR1/2<sup><a href="#ref-81">81</a>,<a href="#ref-82">82</a></sup> that are highly expressed on MF spleen CD34<sup>+</sup> cells<sup><a href="#ref-79">79</a></sup>. These data indicate that reparixin may represent a novel therapy which can antagonize the effects of IL-8 and thereby disrupt the HSC niche function of splenic endothelial cells. A clinical trial to test the effects of reparixin in MF is planned to be opened by the Myeloproliferative Neoplasm Research Consortium.</p></div><div class=section><a name=d23757e1205 class=n-a></a><h3 class=section-title>Boosting the patients immune system</h3><p class="" id=d23757e1210>An important emerging approach in cancer therapy is activation of endogenous anti-tumor activity by treatment with agents that suppress the immune evasion mechanisms activated by cancer cells<sup><a href="#ref-83">83</a></sup>. Checkpoint inhibitors, which block the interaction between programmed cell death (PD)1 and its ligand PD-L1 that is exploited by cancer cells to prevent attack by cytotoxic T-lymphocytes, have shown impressive anti-tumor responses in several solid cancers and B-lymphoid malignancies<sup><a href="#ref-83">83</a></sup>. There is a strong pre-clinical rationale for inhibition of PD1/PD-L1 interaction in MF<sup><a href="#ref-84">84</a><a href="#ref-86">86</a></sup>, and several clinical trials are ongoing (NCT03065400, NCT02421354, and NCT02871323). In addition, recent studies suggest that mutant calreticulin and JAK2 can induce specific anti-tumor T-cell responses, which can be harnessed for the development of mutation-specific peptide vaccines<sup><a href="#ref-87">87</a>,<a href="#ref-88">88</a></sup>. These and other immune therapy approaches, such as bispecific antibodies, are still in early stages of development.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d23757e1240>Harnessing the altered p53TGF- circuitry to treat MF</h2><p class="" id=d23757e1243>Although MF originates at the level of HSCs, the predominance of the malignant HSCs over the reservoir of normal HSCs is sustained by tumor-induced micro-environments of bone marrow and spleen<sup><a href="#ref-89">89</a>,<a href="#ref-90">90</a></sup>. Studies in animal models indicate that these microenvironmental abnormalities may induce MF independently from the presence of driver mutations<sup><a href="#ref-91">91</a></sup>. It is believed that the interaction between MF and abnormal microenvironments determine, at least in part, the clinical sequelae of MF as well as the rate of progression and evolution to MPN-BP<sup><a href="#ref-75">75</a></sup>. In addition to abnormalities described in a previous section, Targeting the inflammatory microenvironment, possibly inter-related abnormalities for which promising investigational agents are available are represented by reduced expression of p53 in malignant HSCs and increased TGF- bioavailability in their supporting microenvironment.</p><div class=section><a name=d23757e1261 class=n-a></a><h3 class=section-title>Targeting the reduced expression of p53 in MF-HSCs</h3><p class="" id=d23757e1266>p53 is a tumor suppressor that regulates cell cycle, apoptosis, DNA repair, and senescence of many cell types<sup><a href="#ref-92">92</a>,<a href="#ref-93">93</a></sup>. Hypomorphic/loss-of-function mutations of <i>p53</i> are associated with tumor progression in most human cancers<sup><a href="#ref-18">18</a></sup>, and inactivating mutations are observed in 20% of MPN-BP while deletion of <i>p53</i> leads to the development of AML in <i>JAK2</i>V617F-harboring mice<sup><a href="#ref-94">94</a></sup>. Although in patients with chronic-phase MPN <i>p53</i> is usually wild-type, as discussed in Targeting the inflammatory microenvironment, malignant HSCs are p53 hypomorphic, as they express low levels of the protein<sup><a href="#ref-95">95</a>,<a href="#ref-96">96</a></sup>.</p><p class="" id=d23757e1304>Studies to determine the levels of p53 in MF patients with no obvious <i>p53</i> mutations were inspired by Takaoka <i>et al</i>., who reported that interferon suppresses tumor progression and activates the immune response by increasing the expression of p53 in mouse models of fibroblast transformation<sup><a href="#ref-97">97</a></sup>. Since interferon is an effective therapy in patients with MPNs<sup><a href="#ref-98">98</a></sup>, it was hypothesized that interferon is at least partially effective in these patients by increasing the otherwise low levels of p53 expressed by the malignant HSCs<sup><a href="#ref-99">99</a></sup>. As in other cancers<sup><a href="#ref-95">95</a>,<a href="#ref-100">100</a></sup>, the mechanisms that reduce p53 in MPNs may be represented by overexpression of its major regulators MDM2 (HDM2 in humans) and MDM4 (HDM4/HDMX), which are expressed at levels higher than normal in MF CD34<sup>+</sup> cells<sup><a href="#ref-99">99</a></sup>. Overexpression of HDM4 and HDM2 in MF may be genetically determined. The two genes are localized on chromosomes 1 and 12, respectively, and gain of 1q and 12q rearrangements are frequently associated with disease progression in MPNs<sup><a href="#ref-101">101</a></sup>. Alternatively, the observation that high TGF-1 induces the expression of HDM2 in breast cancer driving its late metastatic stage<sup><a href="#ref-102">102</a></sup> suggests that, even in the absence of chromosomal duplication, the great levels of TGF- expressed in the microenvironment (see following section) may drive high levels of HDM2 in MF.</p><p class="" id=d23757e1348>The existence of a p53/HDM2 cycle in MF is important because binding of p53 to HDM2 resulting in p53 ubiquitination and degradation is inhibited by a class of compounds called Nutlins. Nutlins (Nutlin-3, RG7112, RG7388, HDM201, and KRT232) bind to the MDM2 p53-binding site, interfering with its interaction with p53, leading to p53 accumulation and activation<sup><a href="#ref-95">95</a>,<a href="#ref-100">100</a>,<a href="#ref-103">103</a><a href="#ref-106">106</a></sup>. Proof-of-principle for the therapeutic use of Nutlins in MF was provided by the observation that the orally available Nutlin RG7388 (idasanutlin) depletes MPN-HSCs in culture<sup><a href="#ref-99">99</a></sup>. In addition, low doses of the Nutlin RG7112 induce apoptosis of MF CD34<sup>+</sup> cells and reduce donor cell chimerism and <i>JAK2</i>V617F allele burden in NSG mice transplanted with MF CD34<sup>+</sup> cells<sup><a href="#ref-107">107</a></sup>. The promising results of an open label phase I study of idasanutlin as a single agent in patients with PV and ET presented by Dr. Mascarenhas <i>et al</i>. in 2017 at ASH<sup><a href="#ref-108">108</a></sup> and the observation that in AML the patients with the highest overexpression of HDM2 are most responsive to therapy with idasanutlin<sup><a href="#ref-109">109</a></sup> suggest that MF patients, who express higher levels of HDM2 than those observed in PV, will respond well to idasanutlin. A clinical trial with idasanutlin in MF will be conducted soon by the Myeloproliferative Neoplasm Research Consortium.</p></div><div class=section><a name=d23757e1394 class=n-a></a><h3 class=section-title>Targeting the TGF- circuitry in MF</h3><p class="" id=d23757e1399>Megakaryocytic hyperplasia was the first histopathological hallmark identified in MF<sup><a href="#ref-110">110</a></sup>. These early studies also identified that this abnormality is associated with increased TGF- content and release due to pathological emperipolesis (the interaction between megakaryocytes and neutrophils)<sup><a href="#ref-111">111</a></sup>. However, in spite of the overwhelming evidence linking TGF- with fibrosis in other systems<sup><a href="#ref-112">112</a>,<a href="#ref-113">113</a></sup>, the link between megakaryocyte and TGF- abnormalities and disease progression in MF has been obscured for some time by the fact that they are not direct targets of the driver mutations.</p><p class="" id=d23757e1417>The link between driver mutations, alterations of megakaryocyte maturation, and disease progression in MF has been recently clarified by the observations that mice expressing <i>JAK2</i>V617F only in megakaryocytes develop MF<sup><a href="#ref-114">114</a></sup>; the driver mutations induce a ribosomopathy that reduces the content of the transcription factor GATA1 (which is essential for terminal maturation) in megakaryocytes, halting their maturation<sup><a href="#ref-115">115</a>,<a href="#ref-116">116</a></sup>; mice lacking the regulatory sequences which specifically drive GATA1 expression in megakaryocytes (<i>Gata1</i><sup>low</sup> mice) develop the same megakaryocyte abnormalities observed in MF and MF with age<sup><a href="#ref-117">117</a>,<a href="#ref-118">118</a></sup>; and, finally, treatment with an inhibitor of Aurora kinase A, a protein overexpressed in MF megakaryocytes, rescues GATA1 expression in these cells, curing MF in animal models<sup><a href="#ref-119">119</a></sup>, suggesting GATA1 as a druggable target in MF<sup><a href="#ref-120">120</a></sup>. This clinical hypothesis was tested by demonstrating that an inhibitor of Aurora Kinase A has some efficacy in MF patients<sup><a href="#ref-121">121</a></sup>. Owing to these exciting results, additional megakaryocyte abnormalities are currently being considered as potential therapeutic targets for MF.</p><p class="" id=d23757e1459>The Vainchenker laboratory hypothesized for the first time that TGF- represents a target to cure MF by demonstrating that malignant HSCs lacking the TGF- gene fail to induce MF upon transplantation in healthy recipients<sup><a href="#ref-122">122</a></sup>. Furthermore, malignant HSCs did not induce MF when transplanted into recipients lacking the TGF- receptor 1 gene<sup><a href="#ref-123">123</a></sup>. These results suggest that TGF- produced by the progeny of the malignant HSCs exerts its pathobiological effects by activating its receptor on a cell population present in the microenvironment. However, attempts to explore the clinical potential of TGF- in MF were hampered for some time by the fact that the gene ablation strategy used by Vainchenker is not practical in clinical settings.</p><p class="" id=d23757e1470>TGF- is known to play a major role in the development of fibrosis in multiple organs<sup><a href="#ref-124">124</a></sup> and in the induction of tumor-supporting microenvironments in other cancers<sup><a href="#ref-125">125</a>,<a href="#ref-126">126</a></sup>. The experiments by Vainchenker do not clarify whether TGF- promotes MF by inducing fibrosis and therefore by hampering the ability of the bone marrow microenvironment to support normal HSCs and/or by inducing a microenvironment supporting the malignant HSCs in extramedullary sites. Using the <i>Gata1<sup>low</sup></i> mouse model, our laboratory has identified at least some of the events linking megakaryocyte abnormalities, increased TGF-, and development of MF. We determined that, although plasma and washes from bone marrow and spleen of <i>Gata1<sup>low</sup></i> mice, as well as those from MF patients, contain levels of total and bioactive TGF- modestly (twofold) greater compared to normal controls<sup><a href="#ref-127">127</a>,<a href="#ref-128">128</a></sup>, the megakaryocytes and their surrounding microenvironment contain levels of TGF- 10002000-fold greater than normal<sup><a href="#ref-128">128</a>,<a href="#ref-129">129</a></sup>, suggesting that it is not increased TGF- content per se but its increased bioavailability that plays a major role in inducing disease progression in MF. By careful electron-microscopy analyses, we also determined that the increased TGF- bioavailability is established by a sequence of abnormal cellular interactions involving megakaryocytes, neutrophils, and activated fibrocytes that are mediated by adhesion receptors that are druggable (<a href="#f1">Figure 1</a>). Ablation of one of them, P-selectin, rescues MF in <i>Gata1<sup>low</sup></i> mice, providing clinical rationale for the use of P-selectin inhibitors, alone or in combination with ruxolitinib, in MF.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/20338/3115b029-7b74-4578-9696-9f7fa0e711b6_figure1.gif"><img alt="3115b029-7b74-4578-9696-9f7fa0e711b6_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/20338/3115b029-7b74-4578-9696-9f7fa0e711b6_figure1.gif"></a><div class=caption><h3>Figure 1. A cellular model for the establishment of increased transforming growth factor (TGF)- bioavailability, which leads to fibrosis and disease progression in myelofibrosis (MF).</h3><p id=d23757e1528>This model was elaborated thanks to the fact that, in contrast with other animal models that develop a MPN phenotype that rapidly progress into its fatal MF phase (discussed in <a href="#ref-114">114</a>), <i>Gata1</i><sup>low</sup> mice slowly develop MF with age<sup><a href="#ref-117">117</a>,<a href="#ref-118">118</a></sup>. From 18 months, <i>Gata1<sup>low</sup></i> mice express pre-MF traits such as splenomegaly, increased rates of thrombosis, and osteosclerosis. From 812 months, they display MF traits including fibrosis and neovascularization, and from 12 months until their natural death they express a late-MF phenotype which includes increased stem/progenitor cell trafficking and extramedullary hematopoiesis in liver. The various phases are characterized by a sequence of abnormal cellular interactions that finally result in increased TGF- bioavailability in the microenvironment. First, a pathological neutrophil-megakaryocyte (Mk) emperipolesis leads to death of the megakaryocytes by para-apoptosis, which releases TGF- into the microenvironment. Second, TGF- activates fibrocytes to produce collagen and to establish contacts with megakaryocytes, leading to the death of additional megakaryocytes and the release of activated lysyl-oxidase 2 (LOX2) into the microenvironment<sup><a href="#ref-135">135</a></sup>. LOX2 polymerizes the collagen produced by the activated fibrocytes into collagen fibers, resulting in fibrosis. The collagen fibers are heavy binders of TGF-, inducing the formation of areas of increased TGF- bioavailability in the microenvironment (see also <a href="#ref-128">128</a>).</p></div></div><p class="" id=d23757e1563>To identify additional druggable TGF- targets, we characterized the TGF- expression profiling of bone marrow and spleen from MF patients and <i>Gata1<sup>low</sup></i> mice<sup><a href="#ref-128">128</a>,<a href="#ref-130">130</a></sup>. These experiments identified that the tissues from the patients and the mouse model express the same distinctive abnormalities which include reduced expression of the canonical SMAD 1, 2, and 4 signaling and increased expression of <i>JUNB</i>, <i>EVI1</i>, and <i>STAT1</i>, three genes downstream of the non-canonical MAPK signaling. These abnormalities predict the activation of non-canonical p38/ERK-dependent rather than canonical SMAD-dependent signaling. The knowledge that activation of SMAD signaling induces normal HSCs into quiescence<sup><a href="#ref-131">131</a>,<a href="#ref-132">132</a></sup> while in systemic sclerosis activation of the p38/ERK pathway promotes the development of fibrosis<sup><a href="#ref-133">133</a>,<a href="#ref-134">134</a></sup> suggests a model for progression from the indolent phase of the disease (pre-MF) to MF depicted in <a href="#f2">Figure 2</a>. In this model, increased levels of TGF- promote disease progression by reducing the number of normal HSCs (inducing them into quiescence and reducing their supportive microenvironment in the bone marrow) while increasing the number of malignant HSCs (which are insensitive to TGF- and are sustained by a specific microenvironment induced by TGF- in the spleen).</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/20338/3115b029-7b74-4578-9696-9f7fa0e711b6_figure2.gif"><img alt="3115b029-7b74-4578-9696-9f7fa0e711b6_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/20338/3115b029-7b74-4578-9696-9f7fa0e711b6_figure2.gif"></a><div class=caption><h3>Figure 2. Circuitry between p53 abnormalities in the malignant hematopoietic stem cells (HSCs) and transforming growth factor (TGF)- in the supporting microenvironment leading to disease progression in myelofibrosis (MF).</h3><p id=d23757e1615>It is suggested that in MF disease progression is driven by a p53/TGF- circuitry. In the pre-MF stage, the driver mutations, possibly by inducing an inflammatory milieu (lipocalin-2 [LNC2]/interleukin-8 [IL-8]), reduce p53 in MF-HSCs, making these cells unresponsive to TGF- and retarding megakaryocyte maturation. Retarded megakaryocyte maturation, associated with high IL-8 expression, induces, in an autocrine fashion, megakaryocytes to increase TGF- bioavailability, which in turn is responsible for suppressing hematopoiesis from normal HSCs (inducing bone marrow failure) and for promoting an MF-HSC-supporting microenvironment in the spleen, facilitating the transition of pre-MF to MF (modified from <a href="#ref-137">137</a>). MK, megakaryocyte; PMF, primary myelofibrosis</p></div></div><p class="" id=d23757e1625>Circumstantial evidence in support of the model for disease progression depicted in <a href="#f2">Figure 2</a> exists. First, we observed that the spleen, but not the bone marrow, from MF patients and <i>Gata1<sup>low</sup></i> mice contains greater numbers of activated fibrocytes that establish physical contacts with megakaryocytes, forming nests, which lodge hematopoietic cells with the morphology of HSCs<sup><a href="#ref-128">128</a>,<a href="#ref-136">136</a></sup>. In the mouse model, the presence of these nests is induced by TGF-. Second, we demonstrated that in contrast to normal HSCs, MF-HSCs are not induced into cycle by treatment with TGF- receptor 1 kinase inhibitors<sup><a href="#ref-137">137</a></sup>.</p><p class="" id=d23757e1647>Based on this overwhelming evidence, a proof-of-principle experiment was conducted that provided findings that one-month treatment with an inhibitor of LK5, the first element of the TGF- receptor I signaling, completely rescues MF in <i>Gata1</i><sup>low</sup> mice<sup><a href="#ref-129">129</a>,<a href="#ref-136">136</a></sup>. Furthermore, a limited clinical trial with a human neutralizing antibody against TGF- (fresolimumab, Sanofi Aventis) provided evidence for sustained improvements in hemoglobin level<sup><a href="#ref-137">137</a>,<a href="#ref-138">138</a></sup> and of reduced bone marrow fibrosis that lasted for at least one year after the drug was discontinued<sup><a href="#ref-137">137</a></sup> in at least two of the three patients treated. A drawback of drugs targeting TGF- is their lack of specificity that makes them prone to off-target effects. The availability of ligand-traps specific for TGF-1, such as AVID200 developed by Formation Biologics<sup><a href="#ref-139">139</a></sup>, makes conducting clinical trials to test the efficacy of TGF- inhibition in MF and eventually to halt the progression from pre-MF to MF in patients without fear of cardiovascular or osteological complications finally possible. AVID200 will be tested in a clinical trial to be opened soon by the Myeloproliferative Neoplasm consortium.</p><p class="" id=d23757e1677>The existence of a circuitry between p53 and TGF- in development and cancer progression has been extensively discussed<sup><a href="#ref-140">140</a><a href="#ref-142">142</a></sup>. In addition to the possibility that high levels of TGF- may be responsible for reducing p53 in cancer cells by inducing HMD2 discussed in a previous section, Targeting the reduced expression of p53 in MF-HSCs<sup><a href="#ref-102">102</a></sup>, other feedbacks between the two pathways have also been described. In some cell models, low levels of p53 are responsible for rendering malignant cells insensitive to the inhibitory effects of TGF- on proliferation<sup><a href="#ref-143">143</a></sup>. It is therefore possible that, also in MF, low levels of p53 make the malignant HSCs TGF- unresponsive. This consideration suggests that combination therapies targeting p53 (Nutlins) and TGF- (AVID200), by disrupting the cross-talks between the two pathways, have a greater potential than single therapies to cure MF. This hypothesis will be tested by ongoing preclinical studies.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d23757e1699>Lessons learned from studying MF are broadly applicable to cancer pathogenesis and therapy</h2><p class="" id=d23757e1702>As previously discussed, the dissemination of malignant hematopoiesis beyond the marrow occurring during MF progression is associated with the establishment of malignant HSC-supporting microenvironments in the spleen. These events are strikingly similar to those occurring in many metastatic solid tumors<sup><a href="#ref-125">125</a>,<a href="#ref-126">126</a></sup>, suggesting that lessons learned from studying MF may be applied to studying the progression of numerous other tumor types.</p><p class="" id=d23757e1712>Induction of tumor-specific microenvironments as well as cell trafficking are complex processes that involve hundreds of genes, many of which are implicated in multiple biological processes. A comparison of gene dysregulation in <i>Gata1<sup>low</sup></i> mice and in the metastatic phase of other solid cancers provides support for the hypothesis that the two pathologies are determined by common mechanisms. Pathway analyses of expression profiling of bone marrow and spleen from <i>Gata1<sup>low</sup></i> mice identified two altered expression signatures involving 2035 genes of the TGF-1 signaling pathway with important hematopoietic functions<sup><a href="#ref-129">129</a></sup>. In bone marrow, there was significant down-regulation of <i>Bmp2</i>, <i>Bmp5</i>, <i>Acvrl1</i>, and <i>Igf1</i>, whereas in the spleen, there was significant overexpression of <i>Cdkn1a</i> and <i>Ltbp1</i> and underexpression of <i>Gdf2</i> and <i>Nodal</i>. Interestingly, several of these events are reported also in other metastatic solid tumors. For example, TGF- is dysregulated in colorectal cancer with similarity to those noted in the bone marrow, including downregulation of <i>Bmp2</i> and <i>Bmp5</i><sup><a href="#ref-144">144</a></sup>; ACVRL1 overexpression is also observed in colorectal cancer, where it has been suggested as a prognostic biomarker for the metastatic phase<sup><a href="#ref-145">145</a></sup>; and TGF- and its signaling crosstalk play a crucial role during the endothelial mesenchymal transition, which promotes the metastatic phase of various solid tumors, particularly in breast and pancreatic carcinoma<sup><a href="#ref-146">146</a></sup>. These similarities strongly suggest that lessons learned from studying MF can be applied to studying the pathogenesis of other tumor types.</p><p class="" id=d23757e1772>Finally, fibrosis is the end stage of all organ failures, including liver, kidney, heart, and lung, which, when associated with MF, have poor prognosis. It is conceivable that the identification of treatments which prevent or delay the progression of MF to PMF may inspire treatments for other organ failures as well.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d23757e1778>Conclusion</h2><p class="" id=d23757e1781>Although MPNs are uniformly associated with the activation of the JAK/STAT signaling pathways, therapy with currently available JAK2 inhibitors is unable to deplete or eliminate MPN-HSCs. New developments in our knowledge on the biology of MPNs have identified an interplay among HSCs and microenvironmental abnormalities that may sustain disease progression. This cycle is druggable by BETi, CXCR1/2 inhibitors, p53 activators, and TGF- inhibitors. These drugs are currently the subject of careful investigation in preclinical models and clinical studies in MF patients as single agents. We foresee that these careful approaches will soon identify the best agents that, alone or in combination, may take us closer to the cure of MF in the near future.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d23757e1 class=n-a></a><h2 class=main-title id=d24214>Author contributions</h2><p class=metadata-entry><a name=d23757e152 class=n-a></a><p id=d23757e153> All of the authors have equally contributed to the literature search, the writing of the conceptualization of ideas, and the discussion of their perspectives, which led to the assembling of this manuscript.</p></p></div><div class=back-section><a name=d23757e1788 class=n-a></a><h2 class=main-title id=d23757e1790>Acknowledgments</h2><p class="" id=d23757e1793>Dr. Mohamed Salama (Mayo Clinic, Rochester, MN) is gratefully acknowledged for critical review of the manuscript and Dr. Ronald Hoffman (Ichan School of Medicine at Mount Sinai, New York, NY) for discussion and encouragement.</p></div><div class=back-section><a name=d23757e1797 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d24703>References</h2><div class="section ref-list"><a name=d23757e1797 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d23757e1804 class=n-a></a>Arber DA, Orazi A, Hasserjian R, <i> et al.</i>: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. <i>Blood.</i> 2016; <b>127</b>(20): 2391405. <a target=xrefwindow id=d23757e1815 href="http://www.ncbi.nlm.nih.gov/pubmed/27069254">PubMed Abstract </a> | <a target=xrefwindow id=d23757e1818 href="https://doi.org/10.1182/blood-2016-03-643544">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d23757e1827 class=n-a></a>Barosi G, Mesa RA, Thiele J, <i> et al.</i>: Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. <i>Leukemia.</i> 2008; <b>22</b>(2): 4378. <a target=xrefwindow id=d23757e1838 href="http://www.ncbi.nlm.nih.gov/pubmed/17728787">PubMed Abstract </a> | <a target=xrefwindow id=d23757e1841 href="https://doi.org/10.1038/sj.leu.2404914">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d23757e1850 class=n-a></a>Adamson JW, Fialkow PJ, Murphy S, <i> et al.</i>: Polycythemia vera: stem-cell and probable clonal origin of the disease. <i>N Engl J Med.</i> 1976; <b>295</b>(17): 9136. <a target=xrefwindow id=d23757e1861 href="http://www.ncbi.nlm.nih.gov/pubmed/967201">PubMed Abstract </a> | <a target=xrefwindow id=d23757e1864 href="https://doi.org/10.1056/NEJM197610212951702">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d23757e1873 class=n-a></a>Jamieson CH, Gotlib J, Durocher JA, <i> et al.</i>: The <i>JAK2</i> V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. <i>Proc Natl Acad Sci U S A.</i> 2006; <b>103</b>(16): 62249. <a target=xrefwindow id=d23757e1887 href="http://www.ncbi.nlm.nih.gov/pubmed/16603627">PubMed Abstract </a> | <a target=xrefwindow id=d23757e1891 href="https://doi.org/10.1073/pnas.0601462103">Publisher Full Text </a> | <a target=xrefwindow id=d23757e1894 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1434515">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726326049"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e1903 class=n-a></a>Vainchenker W, Constantinescu SN, Plo I: Recent advances in understanding myelofibrosis and essential thrombocythemia [version 1; peer review: 2 approved]. <i>F1000Res.</i> 2016; <b>5</b>: pii: F1000 Faculty Rev-700. <a target=xrefwindow id=d23757e1911 href="http://www.ncbi.nlm.nih.gov/pubmed/27134742">PubMed Abstract </a> | <a target=xrefwindow id=d23757e1914 href="https://doi.org/10.12688/f1000research.8081.1">Publisher Full Text </a> | <a target=xrefwindow id=d23757e1917 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4841197">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726326049">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d23757e1931 class=n-a></a>Tefferi A: Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. <i>Am J Hematol.</i> 2016; <b>91</b>(12): 126271. <a target=xrefwindow id=d23757e1939 href="http://www.ncbi.nlm.nih.gov/pubmed/27870387">PubMed Abstract </a> | <a target=xrefwindow id=d23757e1942 href="https://doi.org/10.1002/ajh.24592">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1026013"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e1951 class=n-a></a>James C, Ugo V, Le Coudic JP, <i> et al.</i>: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. <i>Nature.</i> 2005; <b>434</b>(7037): 11448. <a target=xrefwindow id=d23757e1962 href="http://www.ncbi.nlm.nih.gov/pubmed/15793561">PubMed Abstract </a> | <a target=xrefwindow id=d23757e1965 href="https://doi.org/10.1038/nature03546">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1026013">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718718566"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e1978 class=n-a></a>Kralovics R, Passamonti F, Buser AS, <i> et al.</i>: A gain-of-function mutation of JAK2 in myeloproliferative disorders. <i>N Engl J Med.</i> 2005; <b>352</b>(17): 177990. <a target=xrefwindow id=d23757e1989 href="http://www.ncbi.nlm.nih.gov/pubmed/15858187">PubMed Abstract </a> | <a target=xrefwindow id=d23757e1992 href="https://doi.org/10.1056/NEJMoa051113">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718718566">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/720540175"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2005 class=n-a></a>Levine RL, Wadleigh M, Cools J, <i> et al.</i>: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. <i>Cancer Cell.</i> 2005; <b>7</b>(4): 38797. <a target=xrefwindow id=d23757e2016 href="http://www.ncbi.nlm.nih.gov/pubmed/15837627">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2019 href="https://doi.org/10.1016/j.ccr.2005.03.023">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/720540175">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/719900216"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2032 class=n-a></a>Baxter EJ, Scott LM, Campbell PJ, <i> et al.</i>: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. <i>Lancet.</i> 2005; <b>365</b>(9464): 105461. <a target=xrefwindow id=d23757e2043 href="http://www.ncbi.nlm.nih.gov/pubmed/15781101">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2046 href="https://doi.org/10.1016/S0140-6736(05)71142-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/719900216">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1068772"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2059 class=n-a></a>Scott LM, Tong W, Levine RL, <i> et al.</i>: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. <i>N Engl J Med.</i> 2007; <b>356</b>(5): 45968. <a target=xrefwindow id=d23757e2070 href="http://www.ncbi.nlm.nih.gov/pubmed/17267906">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2073 href="https://doi.org/10.1056/NEJMoa065202">Publisher Full Text </a> | <a target=xrefwindow id=d23757e2077 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2873834">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1068772">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1053679"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2091 class=n-a></a>Pikman Y, Lee BH, Mercher T, <i> et al.</i>: <i>MPLW515L</i> is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. <i>PLoS Med.</i> 2006; <b>3</b>(7): e270. <a target=xrefwindow id=d23757e2105 href="http://www.ncbi.nlm.nih.gov/pubmed/16834459">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2109 href="https://doi.org/10.1371/journal.pmed.0030270">Publisher Full Text </a> | <a target=xrefwindow id=d23757e2112 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1502153">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1053679">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718201696"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2125 class=n-a></a>Klampfl T, Gisslinger H, Harutyunyan AS, <i> et al.</i>: Somatic mutations of calreticulin in myeloproliferative neoplasms. <i>N Engl J Med.</i> 2013; <b>369</b>(25): 237990. <a target=xrefwindow id=d23757e2136 href="http://www.ncbi.nlm.nih.gov/pubmed/24325356">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2139 href="https://doi.org/10.1056/NEJMoa1311347">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718201696">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718204849"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2152 class=n-a></a>Nangalia J, Massie CE, Baxter EJ, <i> et al.</i>: Somatic <i>CALR</i> mutations in myeloproliferative neoplasms with nonmutated <i>JAK2</i>. <i>N Engl J Med.</i> 2013; <b>369</b>(25): 2391405. <a target=xrefwindow id=d23757e2170 href="http://www.ncbi.nlm.nih.gov/pubmed/24325359">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2173 href="https://doi.org/10.1056/NEJMoa1312542">Publisher Full Text </a> | <a target=xrefwindow id=d23757e2176 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3966280">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718204849">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734199033"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2189 class=n-a></a>Grinfeld J, Nangalia J, Baxter EJ, <i> et al.</i>: Classification and Personalized Prognosis in Myeloproliferative Neoplasms. <i>N Engl J Med.</i> 2018; <b>379</b>(15): 141630. <a target=xrefwindow id=d23757e2200 href="http://www.ncbi.nlm.nih.gov/pubmed/30304655">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2203 href="https://doi.org/10.1056/NEJMoa1716614">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734199033">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d23757e2216 class=n-a></a>Vannucchi AM, Lasho TL, Guglielmelli P, <i> et al.</i>: Mutations and prognosis in primary myelofibrosis. <i>Leukemia.</i> 2013; <b>27</b>(9): 18619. <a target=xrefwindow id=d23757e2227 href="http://www.ncbi.nlm.nih.gov/pubmed/23619563">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2230 href="https://doi.org/10.1038/leu.2013.119">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d23757e2239 class=n-a></a>Barraco D, Elala YC, Lasho TL, <i> et al.</i>: Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. <i>Blood Cancer J.</i> 2016; <b>6</b>(4): e415. <a target=xrefwindow id=d23757e2250 href="http://www.ncbi.nlm.nih.gov/pubmed/27058230">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2253 href="https://doi.org/10.1038/bcj.2016.22">Publisher Full Text </a> | <a target=xrefwindow id=d23757e2257 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4855254">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726255630"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2267 class=n-a></a>Harutyunyan A, Klampfl T, Cazzola M, <i> et al.</i>: p53 Lesions in Leukemic Transformation. <i>N Engl J Med.</i> 2011; <b>364</b>(5): 48890. <a target=xrefwindow id=d23757e2278 href="http://www.ncbi.nlm.nih.gov/pubmed/21288114">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2281 href="https://doi.org/10.1056/NEJMc1012718">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726255630">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725281367"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2294 class=n-a></a>Rampal R, Ahn J, Abdel-Wahab O, <i> et al.</i>: Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. <i>Proc Natl Acad Sci U S A.</i> 2014; <b>111</b>(50): E540110. <a target=xrefwindow id=d23757e2305 href="http://www.ncbi.nlm.nih.gov/pubmed/25516983">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2308 href="https://doi.org/10.1073/pnas.1407792111">Publisher Full Text </a> | <a target=xrefwindow id=d23757e2312 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4273376">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725281367">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733086978"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2325 class=n-a></a>Tefferi A, Guglielmelli P, Nicolosi M, <i> et al.</i>: GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis. <i>Leukemia.</i> 2018; <b>32</b>(7): 163142. <a target=xrefwindow id=d23757e2336 href="http://www.ncbi.nlm.nih.gov/pubmed/29654267">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2339 href="https://doi.org/10.1038/s41375-018-0107-z">Publisher Full Text </a> | <a target=xrefwindow id=d23757e2343 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6035151">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733086978">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732279339"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2356 class=n-a></a>Guglielmelli P, Lasho TL, Rotunno G, <i> et al.</i>: MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. <i>J Clin Oncol.</i> 2018; <b>36</b>(4): 3108. <a target=xrefwindow id=d23757e2367 href="http://www.ncbi.nlm.nih.gov/pubmed/29226763">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2370 href="https://doi.org/10.1200/JCO.2017.76.4886">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732279339">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735094543"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2383 class=n-a></a>Gagelmann N, Ditschkowski M, Bogdanov R, <i> et al.</i>: Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. <i>Blood.</i> 2019; <b>133</b>(20): 223342. <a target=xrefwindow id=d23757e2394 href="http://www.ncbi.nlm.nih.gov/pubmed/30760453">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2397 href="https://doi.org/10.1182/blood-2018-12-890889">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735094543">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d23757e2410 class=n-a></a>Foucar CE, Stein BL: Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms. <i>Curr Hematol Malig Rep.</i> 2017; <b>12</b>(5): 40614. <a target=xrefwindow id=d23757e2418 href="http://www.ncbi.nlm.nih.gov/pubmed/28948521">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2421 href="https://doi.org/10.1007/s11899-017-0402-1">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d23757e2431 class=n-a></a>Ianotto JC, Boyer-Perrard F, Gyan E, <i> et al.</i>: Efficacy and safety of pegylated-interferon -2a in myelofibrosis: A study by the FIM and GEM French cooperative groups. <i>Br J Haematol.</i> 2013; <b>162</b>(6): 78391. <a target=xrefwindow id=d23757e2442 href="http://www.ncbi.nlm.nih.gov/pubmed/23848933">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2445 href="https://doi.org/10.1111/bjh.12459">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727623423"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2454 class=n-a></a>Silver RT, Barel AC, Lascu E, <i> et al.</i>: The effect of initial molecular profile on response to recombinant interferon- (rIFN) treatment in early myelofibrosis. <i>Cancer.</i> 2017; <b>123</b>(14): 26807. <a target=xrefwindow id=d23757e2465 href="http://www.ncbi.nlm.nih.gov/pubmed/28518222">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2468 href="https://doi.org/10.1002/cncr.30679">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727623423">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1115745"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2481 class=n-a></a>Quints-Cardama A, Tong W, Kantarjian H, <i> et al.</i>: A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. <i>Leukemia.</i> 2008; <b>22</b>(5): 96570. <a target=xrefwindow id=d23757e2492 href="http://www.ncbi.nlm.nih.gov/pubmed/18385750">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2495 href="https://doi.org/10.1038/leu.2008.91">Publisher Full Text </a> | <a target=xrefwindow id=d23757e2499 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4369783">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1115745">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d23757e2512 class=n-a></a>Thepot S, Itzykson R, Seegers V, <i> et al.</i>: Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). <i>Blood.</i> 2010; <b>116</b>(19): 373542. <a target=xrefwindow id=d23757e2523 href="http://www.ncbi.nlm.nih.gov/pubmed/20664061">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2526 href="https://doi.org/10.1182/blood-2010-03-274811">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d23757e2535 class=n-a></a>Daver N, Cortes JE, Pemmaraju N, <i> et al.</i>: Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF). <i>Blood.</i> 2016; <b>128</b>(22): 1127, Accessed July 31, 2019. <a target=xrefwindow id=d23757e2546 href="http://www.bloodjournal.org/content/128/22/1127">Reference Source</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d23757e2555 class=n-a></a>Verstovsek S, Mesa RA, Gotlib J, <i> et al.</i>: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. <i>N Engl J Med.</i> 2012; <b>366</b>(9): 799807. <a target=xrefwindow id=d23757e2566 href="http://www.ncbi.nlm.nih.gov/pubmed/22375971">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2569 href="https://doi.org/10.1056/NEJMoa1110557">Publisher Full Text </a> | <a target=xrefwindow id=d23757e2573 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4822164">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d23757e2583 class=n-a></a>Harrison C, Kiladjian JJ, Al-Ali HK, <i> et al.</i>: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. <i>N Engl J Med.</i> 2012; <b>366</b>(9): 78798. <a target=xrefwindow id=d23757e2594 href="http://www.ncbi.nlm.nih.gov/pubmed/22375970">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2597 href="https://doi.org/10.1056/NEJMoa1110556">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732417928"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2606 class=n-a></a>Verstovsek S, Gotlib J, Mesa RA, <i> et al.</i>: Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. <i>J Hematol Oncol.</i> 2017; <b>10</b>(1): 156. <a target=xrefwindow id=d23757e2617 href="http://www.ncbi.nlm.nih.gov/pubmed/28962635">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2620 href="https://doi.org/10.1186/s13045-017-0527-7">Publisher Full Text </a> | <a target=xrefwindow id=d23757e2624 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5622445">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732417928">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d23757e2637 class=n-a></a>Mart-Carvajal AJ, Anand V, Sol I: Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis. <i>Cochrane Database Syst Rev.</i> 2015; (4): CD010298. <a target=xrefwindow id=d23757e2642 href="http://www.ncbi.nlm.nih.gov/pubmed/25860512">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2645 href="https://doi.org/10.1002/14651858.CD010298.pub2">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d23757e2654 class=n-a></a>Cervantes F, Pereira A: Does ruxolitinib prolong the survival of patients with myelofibrosis? <i>Blood.</i> 2017; <b>129</b>(7): 8327. <a target=xrefwindow id=d23757e2662 href="http://www.ncbi.nlm.nih.gov/pubmed/28031182">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2665 href="https://doi.org/10.1182/blood-2016-11-731604">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d23757e2674 class=n-a></a>Barbui T, Tefferi A, Vannucchi AM, <i> et al.</i>: Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia.</i> 2018; <b>32</b>(5): 105769. <a target=xrefwindow id=d23757e2685 href="http://www.ncbi.nlm.nih.gov/pubmed/29515238">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2688 href="https://doi.org/10.1038/s41375-018-0077-1">Publisher Full Text </a> | <a target=xrefwindow id=d23757e2692 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5986069">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727452011"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2701 class=n-a></a>Mesa RA, Vannucchi AM, Mead A, <i> et al.</i>: Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial. <i>Lancet Haematol.</i> 2017; <b>4</b>(5): e225e236. <a target=xrefwindow id=d23757e2712 href="http://www.ncbi.nlm.nih.gov/pubmed/28336242">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2715 href="https://doi.org/10.1016/S2352-3026(17)30027-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727452011">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732822444"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2729 class=n-a></a>Mascarenhas J, Hoffman R, Talpaz M, <i> et al.</i>: Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. <i>JAMA Oncol.</i> 2018; <b>4</b>(5): 6529. <a target=xrefwindow id=d23757e2740 href="http://www.ncbi.nlm.nih.gov/pubmed/29522138">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2743 href="https://doi.org/10.1001/jamaoncol.2017.5818">Publisher Full Text </a> | <a target=xrefwindow id=d23757e2747 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5885169">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732822444">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731250916"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2760 class=n-a></a>Mesa RA, Kiladjian JJ, Catalano JV, <i> et al.</i>: SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Nave Patients With Myelofibrosis. <i>J Clin Oncol.</i> 2017; <b>35</b>(34): 384450. <a target=xrefwindow id=d23757e2771 href="http://www.ncbi.nlm.nih.gov/pubmed/28930494">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2774 href="https://doi.org/10.1200/JCO.2017.73.4418">Publisher Full Text </a> | <a target=xrefwindow id=d23757e2778 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6553796">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731250916">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732365471"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2791 class=n-a></a>Harrison CN, Vannucchi AM, Platzbecker U, <i> et al.</i>: Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. <i>Lancet Haematol.</i> 2018; <b>5</b>(2): e73e81. <a target=xrefwindow id=d23757e2802 href="http://www.ncbi.nlm.nih.gov/pubmed/29275119">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2805 href="https://doi.org/10.1016/S2352-3026(17)30237-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732365471">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d23757e2818 class=n-a></a>Pardanani A, Harrison C, Cortes JE, <i> et al.</i>: Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. <i>JAMA Oncol.</i> 2015; <b>1</b>(5): 64351. <a target=xrefwindow id=d23757e2829 href="http://www.ncbi.nlm.nih.gov/pubmed/26181658">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2832 href="https://doi.org/10.1001/jamaoncol.2015.1590">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727712072"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e2841 class=n-a></a>Harrison CN, Schaap N, Vannucchi AM, <i> et al.</i>: Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. <i>Lancet Haematol.</i> 2017; <b>4</b>(7): e317e324. <a target=xrefwindow id=d23757e2852 href="http://www.ncbi.nlm.nih.gov/pubmed/28602585">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2855 href="https://doi.org/10.1016/S2352-3026(17)30088-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727712072">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d23757e2868 class=n-a></a>Mascarenhas J, Hoffman R: Don't judge a JAK2 inhibitor by spleen response alone. <i>Lancet Haematol.</i> 2018; <b>5</b>(2): e56e57. <a target=xrefwindow id=d23757e2876 href="http://www.ncbi.nlm.nih.gov/pubmed/29275120">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2879 href="https://doi.org/10.1016/S2352-3026(17)30236-3">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d23757e2889 class=n-a></a>Simmons PJ, Przepiorka D, Thomas ED, <i> et al.</i>: Host origin of marrow stromal cells following allogeneic bone marrow transplantation. <i>Nature.</i> 1987; <b>328</b>(6129): 42932. <a target=xrefwindow id=d23757e2900 href="http://www.ncbi.nlm.nih.gov/pubmed/2886914">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2903 href="https://doi.org/10.1038/328429a0">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d23757e2912 class=n-a></a>Guardiola P, Anderson JE, Bandini G, <i> et al.</i>: Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Socit Franaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. <i>Blood.</i> 1999; <b>93</b>(9): 28318. <a target=xrefwindow id=d23757e2923 href="http://www.ncbi.nlm.nih.gov/pubmed/10216077">PubMed Abstract </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d23757e2932 class=n-a></a>Deeg HJ, Gooley TA, Flowers ME, <i> et al.</i>: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. <i>Blood.</i> 2003; <b>102</b>(12): 39128. <a target=xrefwindow id=d23757e2943 href="http://www.ncbi.nlm.nih.gov/pubmed/12920019">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2946 href="https://doi.org/10.1182/blood-2003-06-1856">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d23757e2955 class=n-a></a>Migliaccio AR, Martelli F, Verrucci M, <i> et al.</i>: Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1<sup>low</sup> mouse model of the disease. <i>Exp Hematol.</i> 2008; <b>36</b>(2): 15871. <a target=xrefwindow id=d23757e2969 href="http://www.ncbi.nlm.nih.gov/pubmed/18206727">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2973 href="https://doi.org/10.1016/j.exphem.2007.10.001">Publisher Full Text </a> | <a target=xrefwindow id=d23757e2976 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2747096">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d23757e2985 class=n-a></a>Krger N, Zabelina T, Alchalby H, <i> et al.</i>: Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. <i>Biol Blood Marrow Transplant.</i> 2014; <b>20</b>(6): 8125. <a target=xrefwindow id=d23757e2996 href="http://www.ncbi.nlm.nih.gov/pubmed/24589549">PubMed Abstract </a> | <a target=xrefwindow id=d23757e2999 href="https://doi.org/10.1016/j.bbmt.2014.02.019">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d23757e3008 class=n-a></a>Krger N, Giorgino T, Scott BL, <i> et al.</i>: Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. <i>Blood.</i> 2015; <b>125</b>(21): 334750; quiz 3364. <a target=xrefwindow id=d23757e3019 href="http://www.ncbi.nlm.nih.gov/pubmed/25784679">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3022 href="https://doi.org/10.1182/blood-2014-10-608315">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3026 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4440886">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d23757e3036 class=n-a></a>Keyzner A, Han S, Shapiro S, <i> et al.</i>: Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis. <i>Biol Blood Marrow Transplant.</i> 2016; <b>22</b>(12): 21806. <a target=xrefwindow id=d23757e3047 href="http://www.ncbi.nlm.nih.gov/pubmed/27596130">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3050 href="https://doi.org/10.1016/j.bbmt.2016.08.029">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d23757e3059 class=n-a></a>Ali H, Aldoss I, Yang D, <i> et al.</i>: Long-Term Survival in Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation Using Fludarabine/Melphalan Conditioning Regimen. <i>Blood.</i> 2017; <b>130</b>(Suppl 1): 199. Accessed July 10, 2019. <a target=xrefwindow id=d23757e3070 href="http://www.bloodjournal.org/content/130/Suppl_1/199/tab-article-info?sso-checked=true">Reference Source</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d23757e3079 class=n-a></a>Gupta H, Klisovic R, Galvin J, <i> et al.</i>: Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis: Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders - Research Consortium (MPD-RC). <i>Blood.</i> 2016; <b>128</b>(22): 1126. <a target=xrefwindow id=d23757e3090 href="http://www.bloodjournal.org/content/128/22/1126">Reference Source</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d23757e3099 class=n-a></a>Krger N, Holler E, Kobbe G, <i> et al.</i>: Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood.</i> 2009; <b>114</b>(26): 526470. <a target=xrefwindow id=d23757e3110 href="http://www.ncbi.nlm.nih.gov/pubmed/19812383">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3113 href="https://doi.org/10.1182/blood-2009-07-234880">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d23757e3122 class=n-a></a>Rondelli D, Goldberg JD, Isola L, <i> et al.</i>: MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. <i>Blood.</i> 2014; <b>124</b>(7): 118391. <a target=xrefwindow id=d23757e3133 href="http://www.ncbi.nlm.nih.gov/pubmed/24963042">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3136 href="https://doi.org/10.1182/blood-2014-04-572545">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3140 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4133490">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d23757e3149 class=n-a></a>Bregante S, Dominietto A, Ghiso A, <i> et al.</i>: Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors. <i>Biol Blood Marrow Transplant.</i> 2016; <b>22</b>(2): 3249. <a target=xrefwindow id=d23757e3160 href="http://www.ncbi.nlm.nih.gov/pubmed/26456259">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3163 href="https://doi.org/10.1016/j.bbmt.2015.09.028">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d23757e3173 class=n-a></a>Takagi S, Ota Y, Uchida N, <i> et al.</i>: Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. <i>Blood.</i> 2010; <b>116</b>(4): 64952. <a target=xrefwindow id=d23757e3184 href="http://www.ncbi.nlm.nih.gov/pubmed/20439618">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3187 href="https://doi.org/10.1182/blood-2009-11-252601">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d23757e3196 class=n-a></a>Robin M, Giannotti F, Deconinck E, <i> et al.</i>: Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. <i>Biol Blood Marrow Transplant.</i> 2014; <b>20</b>(11): 18416. <a target=xrefwindow id=d23757e3207 href="http://www.ncbi.nlm.nih.gov/pubmed/24946719">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3210 href="https://doi.org/10.1016/j.bbmt.2014.06.011">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727488570"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3219 class=n-a></a>Krger N, Panagiota V, Badbaran A, <i> et al.</i>: Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. <i>Biol Blood Marrow Transplant.</i> 2017; <b>23</b>(7): 1095101. <a target=xrefwindow id=d23757e3230 href="http://www.ncbi.nlm.nih.gov/pubmed/28389256">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3233 href="https://doi.org/10.1016/j.bbmt.2017.03.034">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727488570">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d23757e3246 class=n-a></a>Vannucchi AM, Harrison CN: Emerging treatments for classical myeloproliferative neoplasms. <i>Blood.</i> 2017; <b>129</b>(6): 693703. <a target=xrefwindow id=d23757e3254 href="http://www.ncbi.nlm.nih.gov/pubmed/28028027">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3257 href="https://doi.org/10.1182/blood-2016-10-695965">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732784916"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3266 class=n-a></a>Shreenivas A, Mascarenhas J: Emerging drugs for the treatment of Myelofibrosis. <i>Expert Opin Emerg Drugs.</i> 2018; <b>23</b>(1): 3749. <a target=xrefwindow id=d23757e3274 href="http://www.ncbi.nlm.nih.gov/pubmed/29480036">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3277 href="https://doi.org/10.1080/14728214.2018.1445718">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732784916">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d23757e3290 class=n-a></a>Carrancio S, Markovics J, Wong P, <i> et al.</i>: An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. <i>Br J Haematol.</i> 2014; <b>165</b>(6): 87082. <a target=xrefwindow id=d23757e3301 href="http://www.ncbi.nlm.nih.gov/pubmed/24635723">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3304 href="https://doi.org/10.1111/bjh.12838">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3308 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4282119">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d23757e3318 class=n-a></a>Suragani RN, Cadena SM, Cawley SM, <i> et al.</i>: Transforming growth factor- superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. <i>Nat Med.</i> 2014; <b>20</b>(4): 40814. <a target=xrefwindow id=d23757e3329 href="http://www.ncbi.nlm.nih.gov/pubmed/24658078">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3332 href="https://doi.org/10.1038/nm.3512">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d23757e3341 class=n-a></a>Iancu-Rubin C, Mosoyan G, Wang J, <i> et al.</i>: Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. <i>Exp Hematol.</i> 2013; <b>41</b>(2): 155166.e17. <a target=xrefwindow id=d23757e3352 href="http://www.ncbi.nlm.nih.gov/pubmed/23261964">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3355 href="https://doi.org/10.1016/j.exphem.2012.12.002">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732466886"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3364 class=n-a></a>Komrokji R, Garcia-Manero G, Ades L, <i> et al.</i>: Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. <i>Lancet Haematol.</i> 2018; <b>5</b>(2): e63e72. <a target=xrefwindow id=d23757e3375 href="http://www.ncbi.nlm.nih.gov/pubmed/29331635">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3378 href="https://doi.org/10.1016/S2352-3026(18)30002-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732466886">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730774358"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3391 class=n-a></a>Platzbecker U, Germing U, Gtze KS, <i> et al.</i>: Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. <i>Lancet Oncol.</i> 2017; <b>18</b>(10): 133847. <a target=xrefwindow id=d23757e3402 href="http://www.ncbi.nlm.nih.gov/pubmed/28870615">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3405 href="https://doi.org/10.1016/S1470-2045(17)30615-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730774358">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d23757e3418 class=n-a></a>Bose P, Daver N, Pemmaraju N, <i> et al.</i>: Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia. <i>Blood.</i> 2017; <b>130</b>(Suppl 1): 255. Accessed July 11, 2019. <a target=xrefwindow id=d23757e3429 href="http://www.bloodjournal.org/content/130/Suppl_1/255?sso-checked=true">Reference Source</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/5472966"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3438 class=n-a></a>Filippakopoulos P, Qi J, Picaud S, <i> et al.</i>: Selective inhibition of BET bromodomains. <i>Nature.</i> 2010; <b>468</b>(7327): 106773. <a target=xrefwindow id=d23757e3449 href="http://www.ncbi.nlm.nih.gov/pubmed/20871596">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3452 href="https://doi.org/10.1038/nature09504">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3456 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3010259">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/5472966">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727060958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3470 class=n-a></a>Prez-Salvia M, Esteller M: Bromodomain inhibitors and cancer therapy: From structures to applications. <i>Epigenetics.</i> 2017; <b>12</b>(5): 32339. <a target=xrefwindow id=d23757e3478 href="http://www.ncbi.nlm.nih.gov/pubmed/27911230">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3481 href="https://doi.org/10.1080/15592294.2016.1265710">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3484 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5453193">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727060958">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d23757e3497 class=n-a></a>Hayden MS, Ghosh S: Shared principles in NF-kappaB signaling. <i>Cell.</i> 2008; <b>132</b>(3): 34462. <a target=xrefwindow id=d23757e3505 href="http://www.ncbi.nlm.nih.gov/pubmed/18267068">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3508 href="https://doi.org/10.1016/j.cell.2008.01.020">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732320516"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3517 class=n-a></a>Kleppe M, Koche R, Zou L, <i> et al.</i>: Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. <i>Cancer Cell.</i> 2018; <b>33</b>(1): 2943.e7. <a target=xrefwindow id=d23757e3528 href="http://www.ncbi.nlm.nih.gov/pubmed/29249691">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3531 href="https://doi.org/10.1016/j.ccell.2017.11.009">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3535 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5760343">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732320516">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726786742"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3548 class=n-a></a>Saenz DT, Fiskus W, Manshouri T, <i> et al.</i>: BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. <i>Leukemia.</i> 2017; <b>31</b>(3): 67887. <a target=xrefwindow id=d23757e3559 href="http://www.ncbi.nlm.nih.gov/pubmed/27677740">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3562 href="https://doi.org/10.1038/leu.2016.260">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3566 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5345582">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726786742">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d23757e3579 class=n-a></a>Mocellin S, Pooley KA, Nitti D: Telomerase and the search for the end of cancer. <i>Trends Mol Med.</i> 2013; <b>19</b>(2): 12533. <a target=xrefwindow id=d23757e3587 href="http://www.ncbi.nlm.nih.gov/pubmed/23253475">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3590 href="https://doi.org/10.1016/j.molmed.2012.11.006">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732122527"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3599 class=n-a></a>Vasko T, Kaifie A, Stope MB, <i> et al.</i>: Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions. <i>Int J Mol Sci.</i> 2017; <b>18</b>(11): pii: E2267. <a target=xrefwindow id=d23757e3610 href="http://www.ncbi.nlm.nih.gov/pubmed/29143804">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3613 href="https://doi.org/10.3390/ijms18112267">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3617 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5713237">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732122527">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d23757e3631 class=n-a></a>Tefferi A, Lasho TL, Begna KH, <i> et al.</i>: A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. <i>N Engl J Med.</i> 2015; <b>373</b>(10): 90819. <a target=xrefwindow id=d23757e3642 href="http://www.ncbi.nlm.nih.gov/pubmed/26332545">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3645 href="https://doi.org/10.1056/NEJMoa1310523">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727381013"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3654 class=n-a></a>Mosoyan G, Kraus T, Ye F, <i> et al.</i>: Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis. <i>Leukemia.</i> 2017; <b>31</b>(11): 245867. <a target=xrefwindow id=d23757e3665 href="http://www.ncbi.nlm.nih.gov/pubmed/28270692">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3668 href="https://doi.org/10.1038/leu.2017.78">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3672 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5985670">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727381013">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d23757e3685 class=n-a></a>Mascarenhas J, Komrokji RS, Cavo M, <i> et al.</i>: Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels. <i>Blood.</i> 2018; <b>132</b>(Suppl 1): 685685. <a target=xrefwindow id=d23757e3696 href="http://www.bloodjournal.org/content/132/Suppl_1/685?sso-checked=true">Reference Source</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d23757e3705 class=n-a></a>Hasselbalch HC: Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? <i>Blood.</i> 2012; <b>119</b>(14): 321925. <a target=xrefwindow id=d23757e3713 href="http://www.ncbi.nlm.nih.gov/pubmed/22318201">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3716 href="https://doi.org/10.1182/blood-2011-11-394775">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/10476956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3725 class=n-a></a>Tefferi A, Vaidya R, Caramazza D, <i> et al.</i>: Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. <i>J Clin Oncol.</i> 2011; <b>29</b>(10): 135663. <a target=xrefwindow id=d23757e3736 href="http://www.ncbi.nlm.nih.gov/pubmed/21300928">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3739 href="https://doi.org/10.1200/JCO.2010.32.9490">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/10476956">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725309550"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3752 class=n-a></a>Kleppe M, Kwak M, Koppikar P, <i> et al.</i>: JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. <i>Cancer Discov.</i> 2015; <b>5</b>(3): 31631. <a target=xrefwindow id=d23757e3763 href="http://www.ncbi.nlm.nih.gov/pubmed/25572172">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3766 href="https://doi.org/10.1158/2159-8290.CD-14-0736">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3770 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4355105">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725309550">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d23757e3784 class=n-a></a>Lu M, Xia L, Liu YC, <i> et al.</i>: Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. <i>Blood.</i> 2015; <b>126</b>(8): 97282. <a target=xrefwindow id=d23757e3795 href="http://www.ncbi.nlm.nih.gov/pubmed/26022238">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3798 href="https://doi.org/10.1182/blood-2014-12-618595">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3802 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4543230">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d23757e3811 class=n-a></a>Lu M, Xia L, Salama ME, <i> et al.</i>: Splenic Micro Environmental Cells from Patients with Myelofibrosis Elaborate a Cascade of Cytokines and Serve As a Niche for Malignant Hematopoiesis. <i>Blood.</i> 2016; <b>128</b>(22): 953. <a target=xrefwindow id=d23757e3822 href="http://www.bloodjournal.org/content/128/22/953/tab-article-info">Reference Source</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d23757e3831 class=n-a></a>Wang X, Prakash S, Lu M, <i> et al.</i>: Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. <i>J Clin Invest.</i> 2012; <b>122</b>(11): 388899. <a target=xrefwindow id=d23757e3842 href="http://www.ncbi.nlm.nih.gov/pubmed/23023702">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3845 href="https://doi.org/10.1172/JCI64397">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3849 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3484080">Free Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d23757e3858 class=n-a></a>Goldstein L, Perez RP, Yardley DA, <i> et al.</i>: A single-arm, preoperative, pilot study to evaluate the safety and biological effects of orally administered reparixin in early breast cancer patients who are candidates for surgery. <i>Cancer Res.</i> 2016; <b>76</b>(14): Suppl. <a target=xrefwindow id=d23757e3869 href="https://doi.org/10.1158/1538-7445.AM2016-CT057">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d23757e3878 class=n-a></a>Pawlick RL, Wink J, Pepper AR, <i> et al.</i>: Reparixin, a CXCR1/2 inhibitor in islet allotransplantation. <i>Islets.</i> 2016; <b>8</b>(5): 11524. <a target=xrefwindow id=d23757e3889 href="http://www.ncbi.nlm.nih.gov/pubmed/27328412">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3892 href="https://doi.org/10.1080/19382014.2016.1199303">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3896 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5029202">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d23757e3905 class=n-a></a>Mellman I, Coukos G, Dranoff G: Cancer immunotherapy comes of age. <i>Nature.</i> 2011; <b>480</b>(7378): 4809. <a target=xrefwindow id=d23757e3913 href="http://www.ncbi.nlm.nih.gov/pubmed/22193102">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3916 href="https://doi.org/10.1038/nature10673">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3919 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3967235">Free Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727180923"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3929 class=n-a></a>Choi DC, Tremblay D, Iancu-Rubin C, <i> et al.</i>: Programmed cell death-1 pathway inhibition in myeloid malignancies: Implications for myeloproliferative neoplasms. <i>Ann Hematol.</i> 2017; <b>96</b>(6): 91927. <a target=xrefwindow id=d23757e3940 href="http://www.ncbi.nlm.nih.gov/pubmed/28062906">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3943 href="https://doi.org/10.1007/s00277-016-2915-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727180923">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732732870"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e3956 class=n-a></a>Prestipino A, Emhardt AJ, Aumann K, <i> et al.</i>: Oncogenic JAK2<sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Sci Transl Med.</i> 2018; <b>10</b>(429): pii: eaam7729. <a target=xrefwindow id=d23757e3970 href="http://www.ncbi.nlm.nih.gov/pubmed/29467301">PubMed Abstract </a> | <a target=xrefwindow id=d23757e3974 href="https://doi.org/10.1126/scitranslmed.aam7729">Publisher Full Text </a> | <a target=xrefwindow id=d23757e3977 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6034655">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732732870">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d23757e3990 class=n-a></a>Craig R, Tripp SR, Deininger MSM: Programmed death ligand (PD-L1) expression is increased in spleens of myelofibrosis patients. In: <i>United States and Canadian Academy (Annual Meeting)</i>. 2016; 1353. </span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727777578"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e4002 class=n-a></a>Holmstrm MO, Martinenaite E, Ahmad SM, <i> et al.</i>: The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. <i>Leukemia.</i> 2018; <b>32</b>(2): 42937. <a target=xrefwindow id=d23757e4013 href="http://www.ncbi.nlm.nih.gov/pubmed/28676668">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4016 href="https://doi.org/10.1038/leu.2017.214">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727777578">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d23757e4029 class=n-a></a>Cimen Bozkus C, Finnigan JP, Mascarenhas J, <i> et al.</i>: Immune Checkpoint Blockade Enhances Mutated Calreticulin-Induced T Cell Immunity in Myeloproliferative Neoplasms. <i>Blood.</i> 2017; <b>130</b>(Suppl 1): 384. Accessed July 16. 2019. <a target=xrefwindow id=d23757e4040 href="http://www.bloodjournal.org/content/130/Suppl_1/384?sso-checked=true">Reference Source</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d23757e4049 class=n-a></a>Desterke C, Martinaud C, Ruzehaji N, <i> et al.</i>: Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis. <i>Mediators Inflamm.</i> 2015; <b>2015</b>: 415024. <a target=xrefwindow id=d23757e4060 href="http://www.ncbi.nlm.nih.gov/pubmed/26640324">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4063 href="https://doi.org/10.1155/2015/415024">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4067 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4660030">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725809553"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e4077 class=n-a></a>Martinaud C, Desterke C, Konopacki J, <i> et al.</i>: Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis. <i>Cancer Res.</i> 2015; <b>75</b>(22): 475365. <a target=xrefwindow id=d23757e4088 href="http://www.ncbi.nlm.nih.gov/pubmed/26404004">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4091 href="https://doi.org/10.1158/0008-5472.CAN-14-3696">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725809553">F1000 Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1088103"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e4104 class=n-a></a>Walkley CR, Olsen GH, Dworkin S, <i> et al.</i>: A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. <i>Cell.</i> 2007; <b>129</b>(6): 1097110. <a target=xrefwindow id=d23757e4115 href="http://www.ncbi.nlm.nih.gov/pubmed/17574023">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4118 href="https://doi.org/10.1016/j.cell.2007.05.014">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4122 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1974882">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1088103">F1000 Recommendation</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d23757e4135 class=n-a></a>Vousden KH, Lane DP: p53 in health and disease. <i>Nat Rev Mol Cell Biol.</i> 2007; <b>8</b>(4): 27583. <a target=xrefwindow id=d23757e4143 href="http://www.ncbi.nlm.nih.gov/pubmed/17380161">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4146 href="https://doi.org/10.1038/nrm2147">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d23757e4155 class=n-a></a>Reinhardt HC, Schumacher B: The p53 network: Cellular and systemic DNA damage responses in aging and cancer. <i>Trends Genet.</i> 2012; <b>28</b>(3): 12836. <a target=xrefwindow id=d23757e4163 href="http://www.ncbi.nlm.nih.gov/pubmed/22265392">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4166 href="https://doi.org/10.1016/j.tig.2011.12.002">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4169 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4120491">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727188266"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e4178 class=n-a></a>Tsuruta-Kishino T, Koya J, Kataoka K, <i> et al.</i>: Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. <i>Oncogene.</i> 2017; <b>36</b>(23): 330011. <a target=xrefwindow id=d23757e4189 href="http://www.ncbi.nlm.nih.gov/pubmed/28068330">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4192 href="https://doi.org/10.1038/onc.2016.478">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727188266">F1000 Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d23757e4205 class=n-a></a>Shangary S, Wang S: Targeting the MDM2-p53 interaction for cancer therapy. <i>Clin Cancer Res.</i> 2008; <b>14</b>(17): 531824. <a target=xrefwindow id=d23757e4213 href="http://www.ncbi.nlm.nih.gov/pubmed/18765522">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4216 href="https://doi.org/10.1158/1078-0432.CCR-07-5136">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4219 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2676446">Free Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717976991"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e4229 class=n-a></a>Nakatake M, Monte-Mor B, Debili N, <i> et al.</i>: JAK2<sup>V617F</sup> negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. <i>Oncogene.</i> 2012; <b>31</b>(10): 132333. <a target=xrefwindow id=d23757e4243 href="http://www.ncbi.nlm.nih.gov/pubmed/21785463">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4247 href="https://doi.org/10.1038/onc.2011.313">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717976991">F1000 Recommendation</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1015334"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e4260 class=n-a></a>Takaoka A, Hayakawa S, Yanai H, <i> et al.</i>: Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. <i>Nature.</i> 2003; <b>424</b>(6948): 51623. <a target=xrefwindow id=d23757e4271 href="http://www.ncbi.nlm.nih.gov/pubmed/12872134">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4274 href="https://doi.org/10.1038/nature01850">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1015334">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d23757e4287 class=n-a></a>Gowin K, Thapaliya P, Samuelson J, <i> et al.</i>: Experience with pegylated interferon -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. <i>Haematologica.</i> 2012; <b>97</b>(10): 15703. <a target=xrefwindow id=d23757e4298 href="http://www.ncbi.nlm.nih.gov/pubmed/22419578">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4301 href="https://doi.org/10.3324/haematol.2011.061390">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4305 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3487558">Free Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d23757e4314 class=n-a></a>Lu M, Wang X, Li Y, <i> et al.</i>: Combination treatment <i>in vitro</i> with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon- 2a specifically targets JAK2V617F-positive polycythemia vera cells. <i>Blood.</i> 2012; <b>120</b>(15): 3098105. <a target=xrefwindow id=d23757e4328 href="http://www.ncbi.nlm.nih.gov/pubmed/22872685">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4332 href="https://doi.org/10.1182/blood-2012-02-410712">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4335 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3471518">Free Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d23757e4344 class=n-a></a>Wade M, Li YC, Wahl GM: MDM2, MDMX and p53 in oncogenesis and cancer therapy. <i>Nat Rev Cancer.</i> 2013; <b>13</b>(2): 8396. <a target=xrefwindow id=d23757e4352 href="http://www.ncbi.nlm.nih.gov/pubmed/23303139">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4355 href="https://doi.org/10.1038/nrc3430">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4358 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4161369">Free Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734684232"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e4367 class=n-a></a>Marcellino BK, Hoffman R, Tripodi J, <i> et al.</i>: Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. <i>Blood Adv.</i> 2018; <b>2</b>(24): 35819. <a target=xrefwindow id=d23757e4378 href="http://www.ncbi.nlm.nih.gov/pubmed/30563882">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4381 href="https://doi.org/10.1182/bloodadvances.2018024018">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4385 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6306879">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734684232">F1000 Recommendation</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d23757e4399 class=n-a></a>Araki S, Eitel JA, Batuello CN, <i> et al.</i>: TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. <i>J Clin Invest.</i> 2010; <b>120</b>(1): 290302. <a target=xrefwindow id=d23757e4410 href="http://www.ncbi.nlm.nih.gov/pubmed/19955655">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4413 href="https://doi.org/10.1172/JCI39194">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4417 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2798681">Free Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718018228"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e4426 class=n-a></a>Lu M, Breyssens H, Salter V, <i> et al.</i>: Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. <i>Cancer Cell.</i> 2013; <b>23</b>(5): 61833. <a target=xrefwindow id=d23757e4437 href="http://www.ncbi.nlm.nih.gov/pubmed/23623661">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4440 href="https://doi.org/10.1016/j.ccr.2013.03.013">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718018228">F1000 Recommendation</a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d23757e4453 class=n-a></a>Vassilev LT: p53 Activation by small molecules: application in oncology. <i>J Med Chem.</i> 2005; <b>48</b>(14): 44919. <a target=xrefwindow id=d23757e4461 href="http://www.ncbi.nlm.nih.gov/pubmed/15999986">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4464 href="https://doi.org/10.1021/jm058174k">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d23757e4473 class=n-a></a>Ray-Coquard I, Blay JY, Italiano A, <i> et al.</i>: Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with <i>MDM2</i>-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. <i>Lancet Oncol.</i> 2012; <b>13</b>(11): 113340. <a target=xrefwindow id=d23757e4487 href="http://www.ncbi.nlm.nih.gov/pubmed/23084521">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4491 href="https://doi.org/10.1016/S1470-2045(12)70474-6">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d23757e4500 class=n-a></a>Ding Q, Zhang Z, Liu JJ, <i> et al.</i>: Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. <i>J Med Chem.</i> 2013; <b>56</b>(14): 597983. <a target=xrefwindow id=d23757e4511 href="http://www.ncbi.nlm.nih.gov/pubmed/23808545">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4514 href="https://doi.org/10.1021/jm400487c">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d23757e4523 class=n-a></a>Lu M, Xia L, Li Y, <i> et al.</i>: The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon  2a target <i>JAK2V617F</i>-positive progenitor and stem cells. <i>Blood.</i> 2014; <b>124</b>(5): 7719. <a target=xrefwindow id=d23757e4537 href="http://www.ncbi.nlm.nih.gov/pubmed/24869939">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4541 href="https://doi.org/10.1182/blood-2013-11-536854">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4544 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4467881">Free Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d23757e4554 class=n-a></a>Mascarenhas J, Lu M, Virtgaym E, <i> et al.</i>: Open Label Phase I Study of Single Agent Oral RG7388 (idasanutlin) in Patients with Polycythemia Vera and Essential Thrombocythemia. <i>Blood.</i> 2017; <b>130</b>(Suppl 1): 254. <a target=xrefwindow id=d23757e4565 href="http://www.bloodjournal.org/content/130/Suppl_1/254?sso-checked=true">Reference Source</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d23757e4574 class=n-a></a>Reis B, Jukofsky L, Chen G, <i> et al.</i>: Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. <i>Haematologica.</i> 2016; <b>101</b>(5): e1858. <a target=xrefwindow id=d23757e4585 href="http://www.ncbi.nlm.nih.gov/pubmed/26869629">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4588 href="https://doi.org/10.3324/haematol.2015.139717">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4592 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5004378">Free Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d23757e4601 class=n-a></a>Zucker-Franklin D: Ultrastructural studies of hematopoietic elements in relation to the myelofibrosis-osteosclerosis syndrome, megakaryocytes and p latelets (MMM or MOS). <i>AdvBiosci.</i> 1974; <b>16</b>: 127143. </span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d23757e4616 class=n-a></a>Schmitt A, Jouault H, Guichard J, <i> et al.</i>: Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. <i>Blood.</i> 2000; <b>96</b>(4): 13427. <a target=xrefwindow id=d23757e4627 href="http://www.ncbi.nlm.nih.gov/pubmed/10942376">PubMed Abstract </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d23757e4636 class=n-a></a>Massagu J: TGFbeta in Cancer. <i>Cell.</i> 2008; <b>134</b>(2): 21530. <a target=xrefwindow id=d23757e4644 href="http://www.ncbi.nlm.nih.gov/pubmed/18662538">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4647 href="https://doi.org/10.1016/j.cell.2008.07.001">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4650 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3512574">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d23757e4659 class=n-a></a>Flavell RA, Sanjabi S, Wrzesinski SH, <i> et al.</i>: The polarization of immune cells in the tumour environment by TGFbeta. <i>Nat Rev Immunol.</i> 2010; <b>10</b>(8): 55467. <a target=xrefwindow id=d23757e4670 href="http://www.ncbi.nlm.nih.gov/pubmed/20616810">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4673 href="https://doi.org/10.1038/nri2808">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4677 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3885992">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d23757e4687 class=n-a></a>Zhan H, Ma Y, Lin CH, <i> et al.</i>: JAK2<sup>V617F</sup>-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation. <i>Leukemia.</i> 2016; <b>30</b>(12): 233241. <a target=xrefwindow id=d23757e4701 href="http://www.ncbi.nlm.nih.gov/pubmed/27133820">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4705 href="https://doi.org/10.1038/leu.2016.114">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4708 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5158308">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d23757e4717 class=n-a></a>Gilles L, Arslan AD, Marinaccio C, <i> et al.</i>: Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. <i>J Clin Invest.</i> 2017; <b>127</b>(4): 131620. <a target=xrefwindow id=d23757e4728 href="http://www.ncbi.nlm.nih.gov/pubmed/28240607">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4731 href="https://doi.org/10.1172/JCI82905">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4735 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5373858">Free Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d23757e4744 class=n-a></a>Zingariello M, Sancillo L, Martelli F, <i> et al.</i>: The thrombopoietin/MPL axis is activated in the Gata1<sup>low</sup> mouse model of myelofibrosis and is associated with a defective RPS14 signature. <i>Blood Cancer J.</i> 2017; <b>7</b>(6): e572. <a target=xrefwindow id=d23757e4758 href="http://www.ncbi.nlm.nih.gov/pubmed/28622305">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4762 href="https://doi.org/10.1038/bcj.2017.51">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4765 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5520398">Free Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1008449"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e4774 class=n-a></a>Vannucchi AM, Bianchi L, Cellai C, <i> et al.</i>: Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1<sup>low</sup> mice). <i>Blood.</i> 2002; <b>100</b>(4): 112332. <a target=xrefwindow id=d23757e4788 href="http://www.ncbi.nlm.nih.gov/pubmed/12149188">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4792 href="https://doi.org/10.1182/blood-2002-06-1913">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1008449">F1000 Recommendation</a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d23757e4805 class=n-a></a>Martelli F, Ghinassi B, Panetta B, <i> et al.</i>: Variegation of the phenotype induced by the Gata1<sup>low</sup> mutation in mice of different genetic backgrounds. <i>Blood.</i> 2005; <b>106</b>(13): 410213. <a target=xrefwindow id=d23757e4819 href="http://www.ncbi.nlm.nih.gov/pubmed/16109774">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4823 href="https://doi.org/10.1182/blood-2005-03-1060">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725939047"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e4832 class=n-a></a>Wen QJ, Yang Q, Goldenson B, <i> et al.</i>: Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. <i>Nat Med.</i> 2015; <b>21</b>(12): 147380. <a target=xrefwindow id=d23757e4843 href="http://www.ncbi.nlm.nih.gov/pubmed/26569382">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4846 href="https://doi.org/10.1038/nm.3995">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4850 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4674320">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725939047">F1000 Recommendation</a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d23757e4864 class=n-a></a>Ling T, Crispino JD, Zingariello M, <i> et al.</i>: GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy. <i>Expert Rev Hematol.</i> 2018; <b>11</b>(3): 16984. <a target=xrefwindow id=d23757e4875 href="http://www.ncbi.nlm.nih.gov/pubmed/29400094">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4878 href="https://doi.org/10.1080/17474086.2018.1436965">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4882 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6108178">Free Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d23757e4891 class=n-a></a>Gangat N, Stein BL, Marinaccio C, <i> et al.</i>: Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis. <i>Blood.</i> 2018; <b>132</b>(Suppl 1): 688. <a target=xrefwindow id=d23757e4902 href="http://www.bloodjournal.org/content/132/Suppl_1/688">Reference Source</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d23757e4911 class=n-a></a>Chagraoui H, Komura E, Tulliez M, <i> et al.</i>: Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. <i>Blood.</i> 2002; <b>100</b>(10): 3495503. <a target=xrefwindow id=d23757e4922 href="http://www.ncbi.nlm.nih.gov/pubmed/12393681">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4925 href="https://doi.org/10.1182/blood-2002-04-1133">Publisher Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d23757e4934 class=n-a></a>Gastinne T, Vigant F, Lavenu-Bombled C, <i> et al.</i>: Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development. <i>Exp Hematol.</i> 2007; <b>35</b>(1): 6474. <a target=xrefwindow id=d23757e4945 href="http://www.ncbi.nlm.nih.gov/pubmed/17198875">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4948 href="https://doi.org/10.1016/j.exphem.2006.08.016">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727535500"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e4957 class=n-a></a>Wernig G, Chen SY, Cui L, <i> et al.</i>: Unifying mechanism for different fibrotic diseases. <i>Proc Natl Acad Sci U S A.</i> 2017; <b>114</b>(18): 475762. <a target=xrefwindow id=d23757e4968 href="http://www.ncbi.nlm.nih.gov/pubmed/28424250">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4971 href="https://doi.org/10.1073/pnas.1621375114">Publisher Full Text </a> | <a target=xrefwindow id=d23757e4975 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5422830">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727535500">F1000 Recommendation</a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d23757e4988 class=n-a></a>Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. <i>J Clin Invest.</i> 2009; <b>119</b>(6): 14208. <a target=xrefwindow id=d23757e4996 href="http://www.ncbi.nlm.nih.gov/pubmed/19487818">PubMed Abstract </a> | <a target=xrefwindow id=d23757e4999 href="https://doi.org/10.1172/JCI39104">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5002 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2689101">Free Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d23757e5012 class=n-a></a>Scheel C, Weinberg RA: Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. <i>Semin Cancer Biol.</i> 2012; <b>22</b>(56): 396403. <a target=xrefwindow id=d23757e5020 href="http://www.ncbi.nlm.nih.gov/pubmed/22554795">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5023 href="https://doi.org/10.1016/j.semcancer.2012.04.001">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5026 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6220425">Free Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d23757e5035 class=n-a></a>Vannucchi AM, Bianchi L, Paoletti F, <i> et al.</i>: A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. <i>Blood.</i> 2005; <b>105</b>(9): 3493501. <a target=xrefwindow id=d23757e5046 href="http://www.ncbi.nlm.nih.gov/pubmed/15665119">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5049 href="https://doi.org/10.1182/blood-2004-04-1320">Publisher Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d23757e5058 class=n-a></a>Zingariello M, Ruggeri A, Martelli F, <i> et al.</i>: A novel interaction between megakaryocytes and activated fibrocytes increases TGF- bioavailability in the <i>Gata1</i><sup>low</sup> mouse model of myelofibrosis. <i>Am J Blood Res.</i> 2015; <b>5</b>(2): 3461. <a target=xrefwindow id=d23757e5074 href="http://www.ncbi.nlm.nih.gov/pubmed/27069753">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5078 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4769347">Free Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d23757e5087 class=n-a></a>Zingariello M, Martelli F, Ciaffoni F, <i> et al.</i>: Characterization of the TGF-1 signaling abnormalities in the Gata1<sup>low</sup> mouse model of myelofibrosis. <i>Blood.</i> 2013; <b>121</b>(17): 334563. <a target=xrefwindow id=d23757e5101 href="http://www.ncbi.nlm.nih.gov/pubmed/23462118">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5105 href="https://doi.org/10.1182/blood-2012-06-439661">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5108 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3637011">Free Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d23757e5117 class=n-a></a>Ciaffoni F, Cassella E, Varricchio L, <i> et al.</i>: Activation of non-canonical TGF-1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis. <i>Blood Cells Mol Dis.</i> 2015; <b>54</b>(3): 23441. <a target=xrefwindow id=d23757e5128 href="http://www.ncbi.nlm.nih.gov/pubmed/25703685">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5131 href="https://doi.org/10.1016/j.bcmd.2014.12.005">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5135 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4338409">Free Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d23757e5144 class=n-a></a>Bruno E, Horrigan SK, Van den Berg D, <i> et al.</i>: The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. <i>Blood.</i> 1998; <b>91</b>(6): 191723. <a target=xrefwindow id=d23757e5155 href="http://www.ncbi.nlm.nih.gov/pubmed/9490674">PubMed Abstract </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d23757e5165 class=n-a></a>Scandura JM, Boccuni P, Massagu J, <i> et al.</i>: Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. <i>Proc Natl Acad Sci U S A.</i> 2004; <b>101</b>(142): 152316. <a target=xrefwindow id=d23757e5176 href="http://www.ncbi.nlm.nih.gov/pubmed/15477587">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5179 href="https://doi.org/10.1073/pnas.0406771101">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5183 href="http://www.ncbi.nlm.nih.gov/pmc/articles/524079">Free Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718136713"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e5192 class=n-a></a>Gerber EE, Gallo EM, Fontana SC, <i> et al.</i>: Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. <i>Nature.</i> 2013; <b>503</b>(7474): 12630. <a target=xrefwindow id=d23757e5203 href="http://www.ncbi.nlm.nih.gov/pubmed/24107997">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5206 href="https://doi.org/10.1038/nature12614">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5210 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3992987">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718136713">F1000 Recommendation</a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14200956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e5223 class=n-a></a>Akhmetshina A, Palumbo K, Dees C, <i> et al.</i>: Activation of canonical Wnt signalling is required for TGF--mediated fibrosis. <i>Nat Commun.</i> 2012; <b>3</b>: 735. <a target=xrefwindow id=d23757e5234 href="http://www.ncbi.nlm.nih.gov/pubmed/22415826">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5237 href="https://doi.org/10.1038/ncomms1734">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5241 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3316881">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14200956">F1000 Recommendation</a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d23757e5254 class=n-a></a>Eliades A, Papadantonakis N, Bhupatiraju A, <i> et al.</i>: Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase. <i>J Biol Chem.</i> 2011; <b>286</b>(31): 276308. <a target=xrefwindow id=d23757e5265 href="http://www.ncbi.nlm.nih.gov/pubmed/21665949">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5268 href="https://doi.org/10.1074/jbc.M111.243113">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5272 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3149354">Free Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d23757e5281 class=n-a></a>Spangrude GJ, Lewandowski D, Martelli F, <i> et al.</i>: P-Selectin Sustains Extramedullary Hematopoiesis in the <i>Gata1</i><sup>low</sup> Model of Myelofibrosis. <i>Stem Cells.</i> 2016; <b>34</b>(1): 6782. <a target=xrefwindow id=d23757e5297 href="http://www.ncbi.nlm.nih.gov/pubmed/26439305">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5301 href="https://doi.org/10.1002/stem.2229">Publisher Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d23757e5310 class=n-a></a>Ceglia I, Dueck AC, Masiello F, <i> et al.</i>: Preclinical rationale for TGF- inhibition as a therapeutic target for the treatment of myelofibrosis. <i>Exp Hematol.</i> 2016; <b>44</b>(12): 11381155.e4. <a target=xrefwindow id=d23757e5321 href="http://www.ncbi.nlm.nih.gov/pubmed/27592389">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5324 href="https://doi.org/10.1016/j.exphem.2016.08.007">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5328 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5778911">Free Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d23757e5338 class=n-a></a>Mascarenhas J, Li T, Sandy L, <i> et al.</i>: Anti-transforming growth factor- therapy in patients with myelofibrosis. <i>Leuk Lymphoma.</i> 2014; <b>55</b>(2): 4502. <a target=xrefwindow id=d23757e5349 href="http://www.ncbi.nlm.nih.gov/pubmed/23682558">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5352 href="https://doi.org/10.3109/10428194.2013.805329">Publisher Full Text </a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d23757e5361 class=n-a></a>Varricchio L, Mascarenhas J, Migliaccio AR, <i> et al.</i>: AVID200, a Potent Trap for TGF- Ligands Inhibits TGF-1 Signaling in Human Myelofibrosis. <i>Blood.</i> 2018; <b>132</b>(Suppl 1): 1791. <a target=xrefwindow id=d23757e5372 href="http://www.bloodjournal.org/content/132/Suppl_1/1791?sso-checked=true">Reference Source</a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d23757e5381 class=n-a></a>Elston R, Inman GJ: Crosstalk between p53 and TGF- Signalling. <i>J Signal Transduct.</i> 2012; <b>2012</b>: 294097. <a target=xrefwindow id=d23757e5389 href="http://www.ncbi.nlm.nih.gov/pubmed/22545213">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5392 href="https://doi.org/10.1155/2012/294097">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5395 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3321553">Free Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d23757e5404 class=n-a></a>Dupont S, Zacchigna L, Adorno M, <i> et al.</i>: Convergence of p53 and TGF-beta signaling networks. <i>Cancer Lett.</i> 2004; <b>213</b>(2): 12938. <a target=xrefwindow id=d23757e5415 href="http://www.ncbi.nlm.nih.gov/pubmed/15327827">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5418 href="https://doi.org/10.1016/j.canlet.2004.06.008">Publisher Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1013386"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e5427 class=n-a></a>Cordenonsi M, Dupont S, Maretto S, <i> et al.</i>: Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. <i>Cell.</i> 2003; <b>113</b>(3): 30114. <a target=xrefwindow id=d23757e5438 href="http://www.ncbi.nlm.nih.gov/pubmed/12732139">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5441 href="https://doi.org/10.1016/S0092-8674(03)00308-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1013386">F1000 Recommendation</a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d23757e5454 class=n-a></a>Gerwin BI, Spillare E, Forrester K, <i> et al.</i>: Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. <i>Proc Natl Acad Sci U S A.</i> 1992; <b>89</b>(7): 275963. <a target=xrefwindow id=d23757e5465 href="http://www.ncbi.nlm.nih.gov/pubmed/1557382">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5468 href="https://doi.org/10.1073/pnas.89.7.2759">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5472 href="http://www.ncbi.nlm.nih.gov/pmc/articles/48742">Free Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733618259"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e5482 class=n-a></a>Pellatt AJ, Mullany LE, Herrick JS, <i> et al.</i>: The TGF-signaling pathway and colorectal cancer: Associations between dysregulated genes and miRNAs. <i>J Transl Med.</i> 2018; <b>16</b>(1): 191. <a target=xrefwindow id=d23757e5493 href="http://www.ncbi.nlm.nih.gov/pubmed/29986714">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5496 href="https://doi.org/10.1186/s12967-018-1566-8">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5500 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6038278">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733618259">F1000 Recommendation</a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733030812"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e5513 class=n-a></a>Hanna DL, Loupakis F, Yang D, <i> et al.</i>: Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clin Colorectal Cancer.</i> 2018; <b>17</b>(3): e471e488. <a target=xrefwindow id=d23757e5524 href="http://www.ncbi.nlm.nih.gov/pubmed/29636300">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5527 href="https://doi.org/10.1016/j.clcc.2018.03.006">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5531 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6110978">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733030812">F1000 Recommendation</a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727621553"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23757e5544 class=n-a></a>Melzer C, Hass R, von der Ohe J, <i> et al.</i>: The role of TGF- and its crosstalk with RAC1/RAC1b signaling in breast and pancreas carcinoma. <i>Cell Commun Signal.</i> 2017; <b>15</b>(1): 19. <a target=xrefwindow id=d23757e5555 href="http://www.ncbi.nlm.nih.gov/pubmed/28499439">PubMed Abstract </a> | <a target=xrefwindow id=d23757e5558 href="https://doi.org/10.1186/s12964-017-0175-0">Publisher Full Text </a> | <a target=xrefwindow id=d23757e5562 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5429551">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727621553">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 19 Sep 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1662.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1662.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Hematology, Hadassah University Center, Jerusalem, Israel<br/> <sup>2</sup> Unit of Microscopic and Ultrastructural Anatomy, Department of Medicine, University Campus Bio-Medico, Rome, Italy<br/> <sup>3</sup> Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), IRCCS, Meldola (FC), Italy<br/> <sup>4</sup> Dipartimento di Scienze Biomediche e NeuroMotorie, Alma Mater Studiorum - Universit&agrave; di Bologna, Bologna, Italy<br/> <p> <div class=margin-bottom> Zimran Eran <br/> <span>Roles: </span> Conceptualization, Writing  Review & Editing </div> <div class=margin-bottom> Maria Zingariello <br/> <span>Roles: </span> Conceptualization, Writing  Review & Editing </div> <div class=margin-bottom> Maria Teresa Bochicchio <br/> <span>Roles: </span> Writing  Review & Editing </div> <div class=margin-bottom> Claudio Bardelli <br/> <span>Roles: </span> Project Administration </div> <div class=margin-bottom> Anna Rita Migliaccio <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1662/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 19 Sep 2019, 8:1662 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.18581.1">https://doi.org/10.12688/f1000research.18581.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2019 Eran Z <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=20338 data-id=18581 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18581.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1662/v1/pdf?article_uuid=afbd6ce0-7cf7-4ded-8297-d9f865d0299a" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.18581.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Eran Z, Zingariello M, Bochicchio MT <em>et al.</em> Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1662 (<a href="https://doi.org/10.12688/f1000research.18581.1" target=_blank>https://doi.org/10.12688/f1000research.18581.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=18581 id=mobile-track-article-signin-18581 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18581?target=/articles/8-1662.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20338 /> <input name=articleId type=hidden value=18581 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Alessandro Vannucchi</strong>, Department of Hematology, Center of Research and Innovation of Myeloproliferative Neoplasms, University of Florence, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Olatoyosi Odenike</strong>, Section of Hematology Oncology, Department of Medicine, University of Chicago Comprehensive Cancer Center, The University of Chicago Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 19 Sep 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1662.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1662.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=56999-53831></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=49617-47367></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1662/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>19 Sep 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Alessandro Vannucchi</strong>, Department of Hematology, Center of Research and Innovation of Myeloproliferative Neoplasms, University of Florence, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Olatoyosi Odenike</strong>, Section of Hematology Oncology, Department of Medicine, University of Chicago Comprehensive Cancer Center, The University of Chicago Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1662.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1662/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Novel strategies for the treatment of myelofibrosis...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1662/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1662/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1662/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Eran Z et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1662/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1662",
            templates : {
                twitter : "Novel strategies for the treatment of myelofibrosis driven by.... Eran Z et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1662/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/18581/20338")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "20338");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "47363": 0,
                           "47364": 0,
                           "47365": 0,
                           "47366": 0,
                           "47367": 0,
                           "53831": 0,
                           "53832": 1,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "c79222eb-fbf2-4bb1-91c2-c56ac0c20bf5";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1662.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1662.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1662.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1662.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1662.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>